Anti-CLDN6 antibody and use thereof
By designing chimeric or humanized monoclonal antibodies, the cross-reactivity and low expression of normal tissues among members of the highly homologous protein family of CLDN6 protein were solved, and efficient binding and inhibition of CLDN6 expression was achieved, and targeting tumor cells Treatment effect.
Patent Information
- Application Number
- PCT/CN2024/092728
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-21
AI Technical Summary
The prior art is difficult to develop effective antibodies against CLDN6 protein, especially in avoiding cross-reactivity and improving targeting among members of its highly homology protein family. CLDN6 is lowly expressed in normal tissues, resulting in the difficulty of targeted therapy. .
Chimeric monoclonal antibodies or humanized monoclonal antibodies are provided that specifically bind CLDN6 and through specific amino acid sequence combinations and CDR designs, improving the affinity and specificity of the antibodies and reducing cross-reactivity to CLDN3 and other family members.
It has achieved efficient binding of CLDN6, significantly inhibiting its expression and killing related cells, reducing the toxic effect on normal tissues, and improving the therapeutic effect against tumor cells.
Smart Images

Figure PCTCN2024092728-FTAPPB-I100001 
Figure PCTCN2024092728-FTAPPB-I100002 
Figure PCTCN2024092728-FTAPPB-I100003
Abstract
Description
Anti-CLDN6 antibodies and uses thereof priority This application claims the benefit of and priority to PCT application number PCT / CN2023 / 093998, filed on May 12, 2023. The entire contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field The present disclosure generally relates to antibodies. More specifically, the present application relates to chimeric antibodies and humanized antibodies against CLDN6, methods for preparing the same, and uses thereof. Background Art Antibodies play an important role in clinical treatment, in vitro diagnosis, scientific research and other fields, and antibody drugs have become a hot spot for new drug development around the world. Antibody drugs play an important role in tumor killing, autoimmune disease treatment and post-transplant immunosuppression, and they also play an irreplaceable role in the prevention and treatment of viral infection-related diseases. The FDA has currently approved more than 100 antibody therapeutic drugs for marketing. Compared with conventional small molecule drugs, antibody drugs have many advantages such as strong targeting and good therapeutic effects, especially in the treatment of anti-tumor and autoimmune diseases. At the same time, in addition to the significant effect of combined drug use, antibody drugs can also be used as biological missiles through antibody-drug conjugation technology, carrying small molecules such as chemotherapy drugs directly to the lesions, precise treatment, and better treatment effects with less toxic side effects. Claudins (CLDNs) are tight junction proteins that are mainly expressed in endothelial cells or epithelial cells in a tissue-specific manner. As a member of the CLDNs family, a large amount of research data in TCGA shows that the level of CLDN6 in ovarian cancer patients is significantly upregulated compared with normal ovarian tissue. The level of CLDN6 in normal ovarian tissue is 0 TPM (transcripts per million, n=88), while the level of CLDN6 in ovarian tumors is 31.4 TPM (n=426). CLDN6 is highly expressed in fetal tissues such as stomach, pancreas, lung, and kidney. Studies have shown that CLDN6 is expressed at 159.9 TPM (n=137) in testicular cancer and 8.4 TPM (n=57) in uterine sarcoma, but not in the corresponding normal adult tissues. The highest expression of CLDN6 in adult tissues is in the testis, with an expression level of only 0.83 TPM. The role of CLDN6 in cancer has attracted attention, and strong evidence shows that changes in CLDN6 expression are associated with the development of various cancers. Tumor malignant phenotypes affected by CLDN6 include proliferation and apoptosis, migration and invasion, and drug resistance, which are regulated by key signaling pathways mediated by CLDN6. Kaplan-Meier analysis showed significant differences in overall survival and recurrence-free survival between the high- and low-CLDN6 expression groups. The 5-year survival rate of the high-CLDN6 expression group was about 30%, while the 5-year survival rate of the low-expression group was 89%. In addition to endometrial cancer, high expression of CLDN6 is also negatively correlated with the prognosis of gastric cancer and urothelial carcinoma. Given its important role in tumors and its low or no expression in normal tissues, high expression in tumor tissues and negative correlation with tumor prognosis, CLDN6 is an ideal target for tumor treatment. The CLDN6 protein is a four-transmembrane protein with four transmembrane hydrophobic regions and two extracellular loops. Its recombinant protein is extremely difficult to express, so there is no suitable protein antigen for immunization, which brings difficulties to the immunization and screening of antibodies against CLDN6. In addition, the CLDN family proteins have high homology. When targeting CLDN6, it is necessary to pay attention to screening or avoiding binding with other family members with high homology, especially avoiding binding with CLDN3, which is widely expressed in normal tissues, to avoid the toxic effects that may be caused by cross-binding, and screening out anti-CLDN6 antibodies suitable for different tissues or different types of tumors is difficult and necessary. The present disclosure is intended to solve this problem. Summary of the invention The present disclosure relates to these and other aspects of providing antibodies, methods, compositions and articles of manufacture. The benefits provided by the present disclosure are widely applicable to the field of antibody therapy and diagnosis, and can be used in combination with antibodies that react with various targets. The present invention provides antibodies that bind to human CLDN6, preferably chimeric monoclonal antibodies or humanized monoclonal antibodies. Also provided are nucleic acid molecules encoding anti-CLDN6 antibodies, vectors and host cells for expressing anti-CLDN6 antibodies. The antibodies disclosed herein can be used to diagnose cancer and / or determine whether cancer cells express CLDN6, and can also be used to treat a variety of cancers in subjects. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The antibody comprises: (1) CDRH1, which comprises or consists of the sequence X1YNMH, wherein X1 is selected from D or S; (2) CDRH2 comprising or consisting of the sequence YX1X2PX3X4X5X6TX7YNQKFKG, X1 is selected from V or I, X2 is selected from N or Y, X3 is selected from N or G, X4 is selected from N or Q or S or A, X5 is selected from A or G or D or Q or S, X6 is selected from A or G, and X7 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WX1X2YVYYYGX3DY or SEQ ID NO: 23 (i.e., consisting of the sequence WX1X2YVYYYGX3DY or consisting of the sequence of SEQ ID NO: 23), X1 is selected from D or E or S or G, X2 is selected from A or G or S or D or Q, and X3 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27 or SEQ ID NO: 29 (i.e., consists of the sequence SEQ ID NO: 27 or consists of the sequence SEQ ID NO: 29); (5) CDRL2 comprising or consisting of the sequence of SEQ ID NO: 30 or SEQ ID NO: 31 (i.e., consisting of the sequence of SEQ ID NO: 30 or consisting of the sequence of SEQ ID NO: 31); and (6) CDRL3 comprising or consisting of the sequence QQYWX1TPYT or SEQ ID NO: 40 (i.e., consisting of the sequence QQYWX1TPYT or consisting of the sequence of SEQ ID NO: 40), X1 being selected from S or N; Or the antibody comprises: (1) CDRH1, which comprises or consists of the sequence SYX1IX2, X1 is selected from N or G, and X2 is selected from H or S; (2) CDRH2 comprising or consisting of the sequence X1IYPX2X3GX4TX5X6NEX7FKG, wherein X1 is selected from Y or E, X2 is selected from G or R, X3 is selected from N or S, X4 is selected from G or N, X5 is selected from K or Y, X6 is selected from Y or H, and X7 is selected from R or K; (3) CDRH3 comprising or consisting of the sequence of SEQ ID NO: 16 or SEQ ID NO: 19; (4) CDRL1, which comprises or consists of the sequence of SEQ ID NO: 24 or SEQ ID NO: 26; (5) CDRL2, which comprises or consists of the sequence X1X2SNLX3S, wherein X1 is selected from L or G, X2 is selected from A or T, and X3 is selected from E or A; and (6) CDRL3, which comprises or consists of the sequence of SEQ ID NO: 34 or SEQ ID NO: 179; Or the antibody comprises: (1) CDRH1 comprising or consisting of the sequence X1YX2MS, wherein X1 is selected from S or N, and X2 is selected from G or A; (2) CDRH2, which comprises or consists of the sequence TISX1GGSYTX2YPDX3X4KG, and X1 is selected from S or D, X2 is selected from Y or S, X3 is selected from S or N, and X4 is selected from V or I; (3) CDRH3 comprising or consisting of the sequence of SEQ ID NO: 17 or SEQ ID NO: 18; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 25; (5) CDRL2 comprising or consisting of the sequence X1X2TSLET, wherein X1 is selected from G or A, and X2 is selected from A or T; and (6) CDRL3, which comprises or consists of the sequence QQYWS X1PX2T, wherein X1 is selected from T or F, and X2 is selected from P or R. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (1) CDRH1 comprising or consisting of the sequence SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNX2X3ATX4YNQKFKG, X1 is selected from V or I, X2 is selected from N or Q or S or A, X3 is selected from A or G or D or Q or S, and X4 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (1) CDRH1 comprising or consisting of the sequence SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNNGATX2YNQKFKG, X1 is selected from V or I, and X2 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (i) a heavy chain complementary determining region CDR1 (abbreviated as CDRH1), which comprises any one of the sequences shown in SEQ ID NOs: 1-5 and 7, or any sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 1-5 and 7; (ii) a CDRH2 comprising a sequence selected from the group consisting of SEQ ID NOs: 8-13, 15, and 74-76, or any sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NOs: 8-13, 15, and 74-76; and (iii) a CDRH3 comprising a sequence selected from the group consisting of SEQ ID NOs: 16-21, 23, and 77-78, or any sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NOs: 16-21, 23, and 77-78; The light chain variable region comprises: a light chain complementary determining region CDR1 (abbreviated as CDRL1) comprising any one of the sequences shown in SEQ ID NOs: 24-27 and 29, or any sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NOs: 24-27 and 29; A light chain complementary determining region CDR2 (abbreviated as CDRL2), which comprises a sequence selected from SEQ ID NOs: 30-33 or any sequence having at least 90% identity with SEQ ID NOs: 30-33; and The light chain complementary determining region CDR3 (abbreviated as CDRL3) comprises any sequence selected from SEQ ID NOs: 34-38, 40 and 179 or any sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NOs: 34-38, 40 and 179. In some embodiments, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises: (a) comprising a CDRH1 shown in any one of SEQ ID NOs: 1-5 and 7; (b) comprising a CDRH2 as shown in any one of SEQ ID NOs: 8-13, 15, 74-76; (c) comprising a CDRH3 as shown in any one of SEQ ID NOs: 16-21, 23, 77-78; (d) comprising CDRL1 shown in any one of SEQ ID NOs: 24-27 and 29; (e) comprising a CDRL2 shown in any one of SEQ ID NOs: 30-33; and (f) comprising the CDRL3 shown in any one of SEQ ID NOs: 34-38, 40 and 179. In some embodiments, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises: (a) comprising CDRH1 as shown in or consisting of SEQ ID NO: 1; comprising CDRH2 as shown in or consisting of SEQ ID NO: 8; comprising CDRH3 as shown in or consisting of SEQ ID NO: 16; comprising CDRL1 as shown in or consisting of SEQ ID NO: 24; comprising CDRL2 as shown in or consisting of SEQ ID NO: 30; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 34; (b) comprising a CDRH1 of or consisting of SEQ ID NO: 2; a CDRH2 of or consisting of SEQ ID NO: 9; a CDRH3 of or consisting of SEQ ID NO: 17; a CDRL1 of or consisting of SEQ ID NO: 25; a CDRL2 of or consisting of SEQ ID NO: 31; and a CDRL3 of or consisting of SEQ ID NO: 35; (c) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 3; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 10; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 18; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 25; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 32; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 36; (d) comprising a CDRH1 of or consisting of SEQ ID NO: 4; a CDRH2 of or consisting of SEQ ID NO: 11; a CDRH3 of or consisting of SEQ ID NO: 19; a CDRL1 of or consisting of SEQ ID NO: 26; a CDRL2 of or consisting of SEQ ID NO: 33; and a CDRL3 of or consisting of SEQ ID NO: 179; (e) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 5; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 12; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 20; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 27; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 31; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 37; (f) comprising CDRH1 shown in SEQ ID NO: 5 or consisting thereof; comprising CDRH2 shown in SEQ ID NO: 13 or consisting thereof; comprising CDRH3 shown in SEQ ID NO: 21 or consisting thereof; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 38; or (g) comprising CDRH1 as shown in SEQ ID NO: 7 or consisting thereof; comprising CDRH2 as shown in SEQ ID NO: 15 or consisting thereof; comprising CDRH3 as shown in SEQ ID NO: 23 or consisting thereof; comprising CDRL1 as shown in SEQ ID NO: 29 or consisting thereof; comprising CDRL2 as shown in SEQ ID NO: 30 or consisting thereof; and comprising CDRL3 as shown in SEQ ID NO: 40 or consisting thereof; or (h) comprising CDRH1 as shown in or consisting of SEQ ID NO: 5; comprising CDRH2 as shown in or consisting of SEQ ID NO: 12; comprising CDRH3 as shown in or consisting of SEQ ID NO: 20; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 38; or (i) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 7; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 24; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 23; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 29; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 30; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 40; or (j) comprising CDRH1 as shown in or consisting of SEQ ID NO:5; comprising CDRH2 as shown in or consisting of SEQ ID NO:75; comprising CDRH3 as shown in or consisting of SEQ ID NO:20; comprising CDRL1 as shown in or consisting of SEQ ID NO:27; comprising CDRL2 as shown in or consisting of SEQ ID NO:31; and comprising CDRL3 as shown in or consisting of SEQ ID NO:37; or (k) comprising CDRH1 as set forth in or consisting of SEQ ID NO:5; comprising CDRH2 as set forth in or consisting of SEQ ID NO:76; comprising CDRH3 as set forth in or consisting of SEQ ID NO:20; comprising CDRL1 as set forth in or consisting of SEQ ID NO:27; comprising CDRL2 as set forth in or consisting of SEQ ID NO:31; and comprising CDRL3 as set forth in or consisting of SEQ ID NO:37; or (l) comprising CDRH1 as shown in or consisting of SEQ ID NO:5; comprising CDRH2 as shown in or consisting of SEQ ID NO:12; comprising CDRH3 as shown in or consisting of SEQ ID NO:77; comprising CDRL1 as shown in or consisting of SEQ ID NO:27; comprising CDRL2 as shown in or consisting of SEQ ID NO:31; and comprising CDRL3 as shown in or consisting of SEQ ID NO:37; or (m) comprising CDRH1 as shown in or consisting of SEQ ID NO: 5; comprising CDRH2 as shown in or consisting of SEQ ID NO: 12; comprising CDRH3 as shown in or consisting of SEQ ID NO: 78; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 37. In some embodiments, the heavy chain variable region as described above comprises or consists of any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of the amino acid sequences having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity with the sequences of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of the amino acid sequences having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity with the sequences of SEQ ID NOs: 61-66, 68-73, or any one of the amino acid sequences having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity with the sequences of SEQ ID NOs: 61-66, 68-73, or any one of the amino acid sequences having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity with the sequences of SEQ ID NOs: In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: (a) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 61; or (b) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 62; or (c) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 63; or (d) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 64; or (e) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 45 or 80-83 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 65; or (f) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 46 or 45 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 66; or (g) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 48 or 79 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 68; or (h) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 69; or (i) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 70; or (j) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 53 or 54 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 71; or (k) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 53-56 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 72; or (l) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 57-60 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 73. In some embodiments, the antibody or antigen-binding portion thereof has one or more of the following properties: (a) binds to human or monkey CLDN6 with an EC50 of 10 μg / mL or less; (b) Cross-reactivity: The binding properties to human CLDN3, and / or human CLDN4, and / or human CLDN9 are less than the binding properties to CLDN6. (c) killing and / or inhibiting cells expressing human CLDN6 (eg, tumor cells, such as tumor cells expressing CLDN6). In some embodiments, the antibody or antigen-binding portion thereof may have (a) EC50 binding properties: binding to human CLDN6 or monkey CLDN6 with an EC50 of 5 μg / mL or less; binding to human CLDN6 or monkey CLDN6 with an EC50 of 3 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 2 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 1 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.5 μg / mL or less; binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.3 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.1 μg / mL or less. In some embodiments, the (b) cross-reactivity of the antibody or its antigen-binding portion may be: the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN proteins other than CLDN6; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN3 protein; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN9 protein; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN4 protein. In some embodiments of the present invention, the antibody or antigen-binding portion thereof has (c) killing and / or inhibition The cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) can be: induced killing and / or inhibition of cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) by antibody-dependent cell-mediated cytotoxicity (ADCC); and / or, induced killing of cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) by complement-dependent cytotoxicity (CDC). In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof competes with the aforementioned antibody or antigen-binding portion thereof for binding to CLDN6 expressed on the cell surface. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a complementarity determining region sequence in any one of SEQ ID NOs: 41-46, 48-60, 79-83 and a complementarity determining region sequence in any one of SEQ ID NOs: 61-66, 68-73. In another aspect, the present disclosure provides an isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprising or consisting of the sequence SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or comprising or consisting of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3 comprising or consisting of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27, or comprising or consisting of the sequence KASX1HX2NX3WLA, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1 comprising or consisting of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142. Preferably, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprising or consisting of the sequence SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or comprising or consisting of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3 comprising or consisting of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27, or comprising or consisting of the sequence KASX1HX2NX3WLA, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1 comprising or consisting of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142. Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of any one of SEQ ID NOs: 12, 91-94, 119-125; (3) CDRH3 comprising or consisting of any one of SEQ ID NOs: 20, 95-97, 126-131; (4) CDRL1, which comprises or consists of any one of SEQ ID NOs: 27, 98-99, 132-135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31 or 101; (6) CDRL3, which comprises or consists of any one of SEQ ID NOs: 37, 102-104, 136-142. Preferably, the antibody comprises or consists of the CDRs shown in Table I and / or Table J, for example, comprises or consists of CDRH1, CDRH2, CDRH3 in Table I and CDRL1, CDRL2, CDRL3 in Table J. Preferably, the antibody comprises the CDRs shown in Table G or a combination thereof. Preferably, the antibody comprises or consists of the CDRs shown in Table K. In addition, the present disclosure further discloses an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the antibody or the antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises any one of SEQ ID NOs: 105-111, or a sequence consisting of thereof, or any one of SEQ ID NOs: 105-111 having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 105-111; the light chain variable region comprises SEQ ID NO: 69, or a sequence consisting of thereof, or any one of SEQ ID NOs: 69 having at least 85%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 69; or wherein the heavy chain variable region comprises SEQ ID NO: 52 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 52; and the light chain variable region comprises SEQ ID NO: 112-118 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 112-118. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody or a humanized antibody. In some embodiments, the antibody is an improved antibody, such as an improved chimeric monoclonal antibody, or an antibody constructed by amino acid substitution. In some embodiments, the isolated antibody or antigen-binding portion thereof comprises a constant region of IgG, such as an IgG1, IgG2, IgG3, or IgG4 constant region. In a specific embodiment, the constant region of IgG is selected from the constant region of IgG1. In some embodiments, the isolated antibody or antigen-binding portion thereof comprises a constant region of IgG1. In some embodiments, the isolated antibody or antigen-binding portion thereof comprises a kappa-type or lambda-type light chain constant region. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises or consists of a heavy chain selected from the group consisting of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 143-167 or SEQ ID NO: 87 or SEQ ID NO: 89; and a light chain comprising or consists of a sequence selected from the group consisting of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 168-178 or SEQ ID NO: 88 or SEQ ID NO: 90. Peptides with 96%, 97%, 98%, 99% or 100% sequence identity. In one aspect, the present disclosure provides an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the antibody or antigen-binding portion thereof as described above. In one aspect, the present disclosure provides a vector comprising the nucleic acid molecule as described above. In one aspect, the present disclosure provides a host cell comprising the nucleic acid molecule or the vector as described above. In one aspect, the present disclosure provides a conjugate comprising the antibody or antigen-binding fragment thereof as described above coupled to at least one detectable label. In one aspect, the present disclosure provides an antibody drug conjugate comprising an antibody, which includes one or more drug moieties, wherein the drug moiety is directly or via a linker (eg, preferably covalently linked) to the antibody or antigen-binding fragment thereof as described above. In one aspect, the present disclosure provides a multispecific molecule comprising the antibody or antigen-binding fragment as described above. In some embodiments, the multispecific molecule specifically binds CLDN6 and additionally specifically binds one or more other targets. In some embodiments, the multispecific molecule further comprises at least one molecule with a second binding specificity for a second target (a second antibody). In some embodiments, the multispecific molecule is a bispecific antibody. On the one hand, the present disclosure provides a chimeric antigen receptor (CAR), which includes an antibody or an antigen-binding fragment thereof as described above, and an immune cell activation portion, wherein the immune cell activation portion includes a transmembrane domain of an immune cell receptor and / or an intracellular signal transduction domain of an immune cell receptor. On the one hand, the present disclosure provides a targeted drug conjugate, which comprises the antibody or antigen-binding fragment thereof as described above, wherein the targeted drug conjugate is selected from radionuclide drug conjugates (RDC), wherein the radionuclide drug conjugate can be used to diagnose or treat a disease. In one aspect, the present disclosure provides an RNA drug, comprising an antibody or an antigen-binding fragment thereof as described above, wherein the RNA is selected from a nucleic acid-coupled drug, wherein the nucleic acid-coupled drug can be used to diagnose or treat a disease. The nucleic acid-coupled drug is prepared by coupling an RNA nucleic acid to an antibody or an antigen-binding fragment. On the one hand, the present disclosure provides a targeted protein degrader drug conjugate, which comprises an antibody or an antigen-binding fragment thereof as described above, wherein the protein degrader drug conjugate is prepared by coupling a protein degrader to an antibody or an antigen-binding fragment via, for example, a chemical bond. On the other hand, the present disclosure provides a pharmaceutical composition or kit, comprising the antibody or antigen-binding portion thereof as described above, the nucleic acid molecule as described above, the vector as described above, the host cell as described above, the conjugate as described above, the antibody-drug conjugate as described above, the multispecific molecule as described above, or the chimeric antigen receptor as described above; and a pharmaceutically acceptable carrier. In another aspect, the present disclosure provides a method for preparing the antibody or antigen-binding portion thereof as described above, comprising the following steps: expressing the antibody or antigen-binding portion thereof as described above in a host cell as described above; and optionally, (ii) isolating the antibody or antigen-binding portion thereof from the host cell. In yet another aspect, the present disclosure provides a method for detecting CLDN6 in a sample or determining the amount of CLDN6 in a sample, comprising the following steps: contacting the sample with the antibody or antigen-binding fragment or the conjugate, and The formation of a complex between the antibody, antigen-binding fragment or conjugate and CLDN6 is detected, or the amount of the complex is determined. In one embodiment, the sample comprises cells. In another aspect, the present disclosure provides a method for diagnosing, detecting or monitoring a disease characterized by CLDN6 expression or binding of CLDN6 to its cell surface, comprising administering an effective dose of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit to a subject in need thereof. In another aspect, the present disclosure provides the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit for use in a method for diagnosing, detecting or monitoring a disease related to CLDN6 expression or binding of CLDN6 to its cell surface in a subject. In another aspect, the present disclosure provides use of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit in the preparation of an agent for diagnosing, detecting or monitoring a disease characterized by expression of CLDN6 or binding of CLDN6 to its cell surface. In another aspect, the present disclosure provides a method for treating a disease characterized by CLDN6 expression or binding of CLDN6 to its cell surface or determining its prognosis in a subject, comprising administering an effective dose of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit to a subject in need thereof. In another aspect, the present disclosure provides the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit for use in a method for treating a disease related to CLDN6 expression or binding of CLDN6 to its cell surface or determining its prognosis in a subject. In another aspect, the present disclosure provides use of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit in the preparation of an agent for treating a disease associated with CLDN6 expression or determining the prognosis thereof. In some embodiments, the disease associated with CLDN6 expression or CLDN6 binding to its cell surface is cancer, and the cancer is preferably selected from the group consisting of ovarian cancer, lung cancer, gastric cancer, breast cancer, liver cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, bladder cancer, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer and uterine cancer. In some embodiments, the subject is a mammal, preferably a human. BRIEF DESCRIPTION OF THE DRAWINGS FIG1 shows the binding ability of chimeric antibodies to HEK293T-CLDN6. FIG. 2 shows the binding ability of 20A3-2A7 to HEK293T-CLDN6. FIG. 3 shows the improved binding of chimeric mAb RecA101 to HEK293T-CLDN6. FIG. 4 shows the binding ability of humanized antibodies engineered based on 51C10H4 to HEK293T-CLDN6. FIG. 5 shows the binding ability of humanized antibodies engineered based on 54B5A7 to HEK293T-CLDN6. FIG. 6 shows the binding ability of chimeric antibodies to HEK293T-CLDN9. FIG. 7 shows the binding ability of 20A3-2A7 to HEK293T-CLDN9. FIG. 8 shows the improved binding of chimeric mAb RecA101 to HEK293T-CLDN9. FIG. 9 shows the binding ability of chimeric antibodies to HEK293T-CLDN3. FIG. 10 shows the binding ability of 20A3-2A7 to HEK293T-CLDN3. FIG. 11 shows the binding ability of chimeric antibodies to HEK293T-CLDN4. FIG. 12 shows the binding ability of 20A3-2A7 to HEK293T-CLDN4. FIG. 13 shows the binding results of 51C10H4 and 54B5A7 chimeric antibodies to cell lines HEK293T-CLDN6, HEK293T-CLDN9, HEK293T-CLDN3, and HEK293T-CLDN4 at a concentration of 5 μg / mL. FIG. 14 shows the results of chimeric antibody binding on CHO-K1-mouse CLDN6 cells. FIG. 15 shows the results of 20A3-2A7 binding on CHO-K1-mouse CLDN6 cells. FIG. 16 shows the results of chimeric antibody binding on CHO-K1-Cyno CLDN6 cells. FIG. 17 shows the results of 20A3-2A7 binding on CHO-K1-Cyno CLDN6 cells. FIG. 18 shows the binding of humanized antibodies engineered based on 51C10H4 to cells overexpressing mouse CLDN6. FIG. 19 shows the binding of humanized antibodies engineered based on 51C10H4 to cells overexpressing monkey CLDN6. FIG. 20 shows the binding of 54B5A7-based engineered humanized antibodies to cells overexpressing mouse CLDN6. FIG. 21 shows the binding of humanized antibodies engineered based on 54B5A7 to cells overexpressing monkey CLDN6. FIG. 22 shows the binding ability of chimeric antibodies to HepG2. FIG. 23 shows the binding ability of 20A3-2A7 to HepG2. FIG. 24 shows the improved binding of chimeric mAb RecA101 to HepG2. FIG. 25 shows the binding ability of the humanized antibody engineered based on 51C10H4 to HepG2. FIG. 26 shows the binding ability of the humanized antibody engineered based on 54B5A7 to HepG2. FIG. 27 shows the binding ability of the second humanized antibody modified based on 54B5A7 to HepG2. FIG. 28 shows the binding ability of chimeric antibodies to PA-1. FIG. 29 shows the binding ability of 20A3-2A7 to PA-1. FIG. 30 shows the binding ability of the humanized antibody engineered based on 51C10H4 to PA-1. FIG. 31 shows the binding ability of the humanized antibody engineered based on 54B5A7 to PA-1. FIG. 32 shows the binding ability of the improved antibody 20A3-M1 to human lung adenocarcinoma cell H1975. FIG. 33 shows the binding of the improved antibody 20A3-M1 to human colon adenocarcinoma cell line LS174T. FIG. 34 shows the binding ability of the improved antibody 20A3-M1 to human ovarian cancer cell OVCAR3. FIG. 35 shows the binding ability of the improved antibody 20A3-M1 to human prostate cancer cells PC-3. FIG. 36 shows the binding ability of the improved antibody 20A3-M1 to the human pancreatic cancer cell Capan2. FIG. 37 shows the improved binding of antibody 20A3-M1 to HepG2. FIG. 38 shows the improved binding of antibody 20A3-M1 to PA-1. Figure 39 shows antibody-dependent cellular cytotoxicity. FIG40 shows complement dependent cytotoxicity FIG. 41 shows the results of the endocytosis assay. FIG. 42 shows the binding of improved antibodies to CHO-K1-CLDN6. FIG. 43 shows the binding ability of antibodies PiH2012, PiH1004, AB3-7, and IgG1 to human ovarian cancer cells OVCA429. FIG. 44 shows the binding ability of antibodies PiH2012, PiH1004, AB3-7, and IgG1 to human gastric cancer cell MKN7. FIG. 45 shows the changes in body weight of mice after administration of anti-CLDN6 antibodies. FIG. 46 shows the changes in jaundice rate of mice after administration of anti-CLDN6 antibodies. FIG. 47 shows the expression of Abcd1 gene in mice after administration of anti-CLDN6 antibodies. FIG. 48 shows the expression of II13 gene in mice after administration of anti-CLDN6 antibodies. FIG. 49 shows the expression of II33 gene in mice after administration of anti-CLDN6 antibodies. FIG. 50 shows the expression of Occludin gene in mice after administration of anti-CLDN6 antibodies. FIG. 51 shows the expression of Zo1 gene in mice after administration of anti-CLDN6 antibodies. FIG. 52 shows the expression of Mmp7 gene in mice after administration of anti-CLDN6 antibodies. FIG. 53 shows the expression of Col1a1 gene in mice after administration of anti-CLDN6 antibodies. FIG. 54 shows the expression of Col1a2 gene in mice after administration of anti-CLDN6 antibodies. FIG. 55 shows the expression of Col3a1 gene in mice after administration of anti-CLDN6 antibodies. FIG. 56 shows the expression of α-SMA gene in mice after administration of anti-CLDN6 antibodies. FIG. 57 shows mouse tissue sections after administration of anti-CLDN6 antibodies. DETAILED DESCRIPTION In order to make those skilled in the art better understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only embodiments of a part of the present invention, rather than all embodiments. Disclosed herein are specific illustrative embodiments that verify the principles of the present invention. It should be emphasized that the present invention is not limited to the specific embodiments illustrated. In addition, any section titles used herein are not to be construed as limiting the described subject matter. Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention will have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context requires otherwise, terms in the singular shall include plural forms, and terms in the plural shall include singular forms. More specifically, as used in this specification and the appended claims, unless the context clearly indicates otherwise, the singular forms "a", "an" and "the" include plural indicators. In this application, unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "comprising" and other forms (such as "including" and "containing") is not restrictive. In addition, the ranges provided in the specification and the appended claims include endpoints and all values between the endpoints. definition In order to better understand the present invention, definitions and explanations of relevant terms are provided below. As used herein, the term "antibody" or "Ab" generally refers to a Y-shaped tetrameric protein comprising two heavy chains (H) and two light chains (L) polypeptide chains held together by covalent disulfide bonds and non-covalent interactions. The light chain of an antibody can be divided into κ or λ light chains. The heavy chain can be divided into μ, δ, γ, α or ε, which define the isotype of the antibody as IgM, IgD, IgG, IgA or IgE, respectively. In the light and heavy chains, the variable region is connected to the constant region by a "J" region of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of 3 domains (CH1, CH2 and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The VH and VL regions can be further divided into highly variable regions (called complementarity determining regions, or CDRs) separated by relatively conserved regions (called framework regions, or FRs). Each VH and VL consists of three CDRs and four FRs in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from N-terminus to C-terminus. The variable regions (VH and VL) of each heavy chain / light chain pair are: The antigen binding site / part is formed respectively. The distribution of amino acids in various regions or domains follows the numbering definitions in common systems such as Kabat, IMGT or Chothia. In the specific embodiments of the present disclosure, the determination of CDR sequences uses the numbering definitions in the Kabat system. Antibodies can have different antibody isotypes, such as IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtypes), IgA1, IgA2, IgD, IgE or IgM antibodies. Antibodies in the present disclosure also include antigen binding portions. Antigen binding portions refer to polypeptides comprising a portion / fragment of a full-length antibody, which retains the ability to specifically bind to the "antigen specifically bound to the full-length antibody", and / or it competes with the full-length antibody for binding to the same antigen. Under some conditions, the antigen binding portion includes Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, double antibodies and such polypeptides comprising at least a portion of antibodies sufficient to confer specific antigen binding ability to the polypeptide. Antigen-binding portions of antibodies can be obtained from a given antibody by conventional techniques known to those skilled in the art (eg, recombinant DNA techniques or enzymatic or chemical cleavage methods) and can be screened for specificity in the same manner as intact antibodies. As used herein, the term "isotype" refers to the antibody class (eg, IgM or IgG1) encoded by the heavy chain constant region genes. As used herein, the term "monoclonal antibody" or "mAb" refers to an antibody molecule / preparation of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. The antibodies of the present invention may be derived from different species, including but not limited to mice, rats, rabbits, guinea pigs, and humans. As used herein, the term "epitope" refers to an antigenic determinant in a molecule, which refers to a portion of a molecule that is recognized by the immune system (e.g., recognized by an antibody), such as a discontinuous three-dimensional site on an antigen recognized by the immune system. In the present invention, the epitope is preferably derived from a CLDN protein, more preferably a CLDN6 protein. The term "chimeric antibody" as used herein refers to antibodies in which the variable region sequences are from one species and the constant region sequences are from another species, for example, antibodies in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody. The term "humanized antibody" is intended to refer to antibodies in which CDR sequences / antigen binding portions or sites derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. In addition, additional framework region modifications may also be made within the human framework sequences. As used herein, the term "CLDN" refers to claudins, including CLDN6, CLDN9, CLDN4 and CLDN3, preferably human CLDN. As used herein, the term "anti-CLDN6 antibody" or "CLDN6 antibody" refers to an antibody capable of binding to CLDN6 or to a cell expressing CLDN6 as defined herein. As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as a reaction between an antibody and an antigen to which it is directed. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less KD value binds to the antigen. As used herein, the term "isolated" refers to a state obtained from the natural state by artificial means. If a certain "isolated" substance or component exists in nature, it may be because its natural environment has changed, or the substance has been separated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide exists naturally in a living organism, and the same high-purity polynucleotide or polypeptide separated from the natural state is called an isolated polynucleotide or polypeptide. The term "isolated" excludes neither mixed artificial or synthetic substances nor other impure substances that do not affect the activity of the isolated substance. As used herein, the term "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated antibody that specifically binds to a CLDN6 protein is substantially free of antibodies that specifically bind to antigens other than the CLDN6 protein). However, an isolated antibody that specifically binds to a human CLDN6 protein may have cross-reactivity to other antigens, such as CLDN6 proteins from other species or other members of the CLDN family. In addition, the isolated antibody may be substantially free of other cellular materials and / or chemicals. As used herein, the term "vector" refers to a nucleic acid vector into which a polynucleotide can be inserted. When a vector allows the expression of a protein encoded by a polynucleotide inserted therein, the vector is referred to as an expression vector. The vector can be transformed, transduced or transfected into a host cell to express the genetic material elements carried in the host cell. Vectors are well known to those skilled in the art, including but not limited to plasmids, bacteriophages, cosmids, artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phages or M13 phages and animal viruses. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papovaviruses (such as SV40). The vector may contain multiple elements for controlling expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may contain an origin of replication. As used herein, the term "host cell" refers to a cell system that can be engineered to produce a target protein, protein fragment or peptide. Host cells include, but are not limited to, cultured cells, such as mammalian cultured cells derived from rodents (rat, mouse, guinea pig or hamster), such as CHO, BHK, NSO, SP2 / 0, YB2 / 0; or human tissue or hybridoma cells, yeast cells and insect cells, as well as cells contained in transgenic animals or cultured tissues. The term covers not only specific test cells, but also the offspring of such cells. Because certain modifications may occur in subsequent generations due to mutations or environmental influences, such offspring may be different from parental cells, but are still included in the scope of the term "host cell". As used herein, the term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules determined by alignment and comparison of the sequences. "Percent identity" refers to the percentage of identical residues between amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest molecules being compared. For these calculations, gaps in the alignment, if any, are preferably addressed by a specific mathematical model or computer program (i.e., an "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, AM, ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, DW, ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, AM, and Griffin, HG, eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al, 1988, SIAM J. Applied Math. 48:1073. As used herein, the term "immunogenicity" refers to the ability to stimulate the formation of specific antibodies or sensitized lymphocytes in an organism. It not only refers to the property of antigens to stimulate the activation, proliferation and differentiation of specific immune cells to ultimately produce immune effector substances such as antibodies and sensitized lymphocytes, but also refers to the specific immune response of antibodies or sensitized T lymphocytes in the presence of antigens. It is formed in the immune system of an organism after stimulating the organism. Immunogenicity is the most important property of an antigen. Whether an antigen can successfully induce an immune response in the host depends on three factors: the nature of the antigen, the reactivity of the host, and the means of immunity. As used herein, the term "transfection" refers to the process of introducing nucleic acids into eukaryotic cells, particularly mammalian cells. Protocols and techniques for transfection include, but are not limited to, lipid transfection and chemical and physical methods such as electroporation. Many transfection techniques are well known in the art and disclosed herein. See, for example, Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al, 1981, Gene 13:197. In a specific embodiment of the invention, the human XO40 gene is transfected into 293F cells. As used herein, the term "hybridoma" and the term "hybridoma cell line" are used interchangeably. When referring to the term "hybridoma" and the term "hybridoma cell line", they also include subclones and progeny cells of the hybridoma. As used herein, in addition to the specified meanings, the term "expression" includes production of DNA or production of RNA or production of protein / peptide, which includes transient or stable expression, and also includes "abnormal expression" or "abnormal expression" or "partial expression". As for the vector for expressing the antibody, a vector type in which the antibody heavy chain and light chain exist in different vectors or a vector type in which the heavy chain and light chain exist in the same vector can be used. As used herein, the term "SPR" or "surface plasmon resonance" refers to and includes an optical phenomenon that allows analysis of real-time biospecific interactions by detecting changes in protein concentration within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). As used herein, the term "fluorescence activated cell sorting" or "FACS" refers to a specialized type of flow cytometry. It provides a method for sorting a heterogeneous mixture of biological cells into two or more containers one cell at a time according to the specific light scattering and fluorescence characteristics of each cell (Flow Metric. "Sorting Out Fluorescence Activated Cell Sorting". 2017-11-09). Instruments for performing FACS are known to those skilled in the art and can be commercially available to the public. Examples of such instruments include FACS Star Plus, FACScan and FACSort instruments from Becton Dickinson (Foster City, Calif.), Epics C from Coulter Epics Division (Hialeah, FLa), and MoFlo from Cytomation (Colorado Springs, Colo.). As used herein, the term "immune effector function" includes any function mediated by components of the immune system that results in inhibition of tumor growth and / or inhibition of tumorigenesis, including inhibition of tumor dissemination and metastasis. Preferably, the immune effector function results in killing tumor cells. Preferably, the immune effector function in the present invention is an antibody-mediated effector function. Such functions include complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), induction of apoptosis in cells carrying tumor-associated antigens (e.g., by binding of antibodies to surface antigens) and / or inhibition of proliferation of cells carrying tumor-associated antigens, preferably ADCC and / or CDC. Antibodies can also simply act by binding to tumor-associated antigens on the surface of tumor cells. For example, antibodies can block the function of tumor-associated antigens or induce apoptosis simply by binding to tumor-associated antigens on the surface of tumor cells. As used herein, the term "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig bound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) enables these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill the target cells with cytotoxins. Antibodies "arm" the cytotoxic cells and are absolutely required for this killing. The primary cells mediating ADCC, NK cells, express only FcγRIII, while monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu.Rev.Immunol 9:457-92 (1991). In order to assess the ADCC activity of the molecule of interest, an in vitro ADCC assay can be performed, such as the assay described in U.S. Pat. No. US5,500,362 or US5,821,337. Effector cells that can be used for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of the molecule of interest can be assessed in vivo, such as in an animal model disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998). The term "complement dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate subclass) that binds to its cognate antigen. To assess complement activation, a CDC assay, such as that described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996), can be performed. The term "subject" includes any mammal, such as a human or non-human animal, preferably a human. As used herein, the term "cancer" refers to any neoplastic or malignant cell growth, proliferation, or metastasis-mediated medical condition, both solid tumors and non-solid tumors such as leukemia. The terms "treatment" and "treatment" as used herein in the context of treating a condition generally refer to treatment and therapy of a human or animal in which some desired therapeutic effect is achieved, for example, inhibition of disease progression, including decreased rate of progression, stagnation of rate of progression, regression of disease, improvement of disease, and cure of disease. Treatment as a preventive measure (i.e., prevention) is also included. For cancer, "treatment" may refer to inhibiting or slowing tumor or malignant cell growth, proliferation, or metastasis, or some combination thereof. For tumors, "treatment" includes removing all or part of a tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of a tumor, or some combination thereof. As used herein, the term "therapeutically effective amount" relates to an amount of an active compound or a material, composition or dosage form comprising an active compound, which, when administered according to the desired treatment regimen, is effective for producing some desired therapeutic effect commensurate with a reasonable benefit / risk ratio. For example, when used in conjunction with the treatment or detection of a disease or condition of interest, an "effective amount" or "effective dose" refers to an amount or concentration of an antibody or antigen-binding portion thereof that is effective for treating or detecting the disease or condition. As used herein, the terms "prevent," "control," or "prevention" with respect to a disease condition in a mammal means preventing or delaying the onset of the disease or preventing the manifestation of clinical or subclinical symptoms thereof. As used herein, "inhibit" means the ability to cause a decrease, such as a decrease in the level of cell proliferation, including a decrease of 5% or more, 10% or more, 20% or more, 50% or more, 75% or more, and also includes complete or substantially complete inhibition, i.e., a decrease to 0 or substantially to 0. As used herein, the term "pharmaceutically acceptable" means that the carrier, diluent, excipient and / or salt thereof is chemically and / or physically compatible with the other ingredients of the formulation and physiologically compatible with the recipient. As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with a subject and an active agent and is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19 th Ed. Pennsylvania: Mack Publishing Company, 1995), and includes but is not limited to pH adjusters, surfactants, adjuvants and ionic strength enhancers. For example, pH adjusters include but are not limited to phosphate buffer; surfactants include but are not limited to cationic, anionic or nonionic surfactants, such as Tween-80; ionic strength enhancers include but are not limited to sodium chloride. As used herein, the term "adjuvant" refers to a nonspecific immune enhancer that is delivered to an organism along with an antigen. Or when delivered to an organism in advance, it can enhance the immune response to the antigen in the organism or change the type of immune response. There are a variety of adjuvants, including but not limited to aluminum adjuvants (such as aluminum hydroxide), Freund's adjuvants (such as Freund's complete adjuvant and Freund's incomplete adjuvant), Corynebacterium brevis, lipopolysaccharide, cytokines, etc. Freund's adjuvant is the most commonly used adjuvant in animal experiments. Aluminum hydroxide adjuvant is more commonly used in clinical trials. Anti-CLDN6 Antibodies In some aspects, the invention includes isolated antibodies or antigen-binding portions thereof. In the context of the present application, "antibodies" may include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized and primatized antibodies, CDR-grafted antibodies, human antibodies, recombinantly produced antibodies, intracellular antibodies, multispecific antibodies, bispecific antibodies, monovalent antibodies, multivalent antibodies, anti-idiotypic antibodies, synthetic antibodies, including mutant proteins and variants thereof, improved antibodies; and derivatives thereof (including Fc fusion proteins and other modifications), as well as any other immunoreactive molecules, as long as they show preferential association or binding with CLDN6 protein. In addition, unless the context otherwise dictates, the term also includes antibodies of all classes (i.e., IgA, IgD, IgE, IgG, and IgM) and all subclasses (i.e., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). In a preferred embodiment, the antibody is a monoclonal antibody. In a more preferred embodiment, the antibody is a chimeric monoclonal antibody or a humanized monoclonal antibody or an improved chimeric monoclonal antibody. In some embodiments, the antibody comprises: (1) CDRH1 comprising or consisting of the sequence X1YNMH, wherein X1 is selected from D or S; (2) CDRH2 comprising or consisting of the sequence YX1X2PX3X4X5X6TX7YNQKFKG, X1 is selected from V or I, X2 is selected from N or Y, X3 is selected from N or G, X4 is selected from N or Q or S or A, X5 is selected from A or G or D or Q or S, X6 is selected from A or G, and X7 is selected from S or N; (3) CDRH3 comprising the sequence WX1X2YVYYYGX3DY or SEQ ID NO: 23 or consisting of any of them, X1 is selected from D or E or S or G, X2 is selected from A or G or S or D or Q, and X3 is selected from L or M; (4) CDRL1, which comprises the sequence of SEQ ID NO: 27 or SEQ ID NO: 29 or consists of any of them; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 30 or SEQ ID NO: 31; and (6) CDRL3, which comprises the sequence QQYWX1TPYT or SEQ ID NO: 40 or consists of any of them, X1 is selected from S or N; Or the antibody comprises: (1) CDRH1, which comprises or consists of the sequence SYX1IX2, X1 is selected from N or G, and X2 is selected from H or S; (2) CDRH2 comprising or consisting of the sequence X1IYPX2X3GX4TX5X6NEX7FKG, wherein X1 is selected from Y or E, X2 is selected from G or R, X3 is selected from N or S, X4 is selected from G or N, X5 is selected from K or Y, X6 is selected from Y or H, and X7 is selected from R or K; (3) CDRH3 comprising or consisting of the sequence of SEQ ID NO: 16 or SEQ ID NO: 19; (4) CDRL1, which comprises the sequence of SEQ ID NO: 24 or SEQ ID NO: 26 or consists of any of them; (5) CDRL2, which comprises or consists of the sequence X1X2SNLX3S, X1 is selected from L or G, and X2 is selected from A or T, X3 is selected from E or A; and (6) CDRL3, which comprises the sequence of SEQ ID NO: 34 or SEQ ID NO: 179 or consists of any of them; Or the antibody comprises: (1) CDRH1 comprising or consisting of the sequence X1YX2MS, wherein X1 is selected from S or N, and X2 is selected from G or A; (2) CDRH2 comprising or consisting of the sequence TISX1GGSYTX2YPDX3X4KG, X1 is selected from S or D, X2 is selected from Y or S, X3 is selected from S or N, and X4 is selected from V or I; (3) CDRH3 comprising the sequence of SEQ ID NO: 17 or SEQ ID NO: 18 or consisting of any of them; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 25; (5) CDRL2 comprising or consisting of the sequence X1X2TSLET, wherein X1 is selected from G or A, and X2 is selected from A or T; and (6) CDRL3, which comprises or consists of the sequence QQYWS X1PX2T, wherein X1 is selected from T or F, and X2 is selected from P or R. In some embodiments, the antibody comprises: (1) CDRH1 comprising or consisting of the sequence SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNX2X3ATX4YNQKFKG, X1 is selected from V or I, X2 is selected from N or Q or S or A, X3 is selected from A or G or D or Q or S, and X4 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N. In some embodiments, the antibody comprises: (1) CDRH1 comprising or consisting of the sequence SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNNGATX2YNQKFKG, X1 is selected from V or I, and X2 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N. In some embodiments, the isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: (i) CDRH1 comprising or consisting of any one of the sequences shown in SEQ ID NOs: 1-5 and 7, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NOs: 1-5 and 7; (ii) CDRH2 comprising or consisting of any one of the sequences shown in SEQ ID NOs: 8-13, 15, 74-76, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NOs: 8-13, 15, 74-76; and (iii) CDRH3, which comprises or consists of any one of the sequences shown in SEQ ID NOs: 16-21, 23, 77-78, or any sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NOs: 16-21, 23, 77-78 or consisting thereof; The light chain variable region comprises: (i) CDRL1, which comprises or consists of any one of the sequences shown in SEQ ID NOs: 24-27 and 29, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NOs: 24-27 and 29; (ii) CDRL2, which comprises or consists of any one of the sequences shown in SEQ ID NOs: 30-33, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NOs: 30-33; and (iii) CDRL3, which comprises or consists of any one of the sequences shown in SEQ ID NOs: 34-38 and 40, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity with SEQ ID NOs: 34-38, 40 and 179, or consists of any one of the sequences. The variable regions and CDRs in an antibody sequence can be identified according to general rules developed in the art (such as the Kabat numbering system as described above or by aligning the sequence with a database of known variable regions. In other embodiments, the CDR amino acid sequence may be at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the corresponding sequences described above. As an illustrative example, the antibody may comprise a CDRH1 having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a CDRH1 selected from SEQ ID NOs: 1-5 and 7. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 1; a CDRH2 comprising or consisting of SEQ ID NO: 8; a CDRH3 comprising or consisting of SEQ ID NO: 16; a CDRL1 comprising or consisting of SEQ ID NO: 24; a CDRL2 comprising or consisting of SEQ ID NO: 30; and a CDRL3 comprising or consisting of SEQ ID NO: 34. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 2; a CDRH2 comprising or consisting of SEQ ID NO: 9; a CDRH3 comprising or consisting of SEQ ID NO: 17; a CDRL1 comprising or consisting of SEQ ID NO: 25; a CDRL2 comprising or consisting of SEQ ID NO: 31; and a CDRL3 comprising or consisting of SEQ ID NO: 35. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 3; a CDRH2 comprising or consisting of SEQ ID NO: 10; a CDRH3 comprising or consisting of SEQ ID NO: 18; a CDRL1 comprising or consisting of SEQ ID NO: 25; a CDRL2 comprising or consisting of SEQ ID NO: 32; and a CDRL3 comprising or consisting of SEQ ID NO: 36. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 4; a CDRH2 comprising or consisting of SEQ ID NO: 11; a CDRH3 comprising or consisting of SEQ ID NO: 19; a CDRL1 comprising or consisting of SEQ ID NO: 26; a CDRL2 comprising or consisting of SEQ ID NO: 33; and a CDRL3 comprising or consisting of SEQ ID NO: 179. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: CDRH1 comprising or consisting of SEQ ID NO: 5; CDRH1 comprising or consisting of SEQ ID NO: 12 CDRH2 consisting of the same; CDRH3 consisting of or comprising SEQ ID NO: 20; CDRL1 consisting of or comprising SEQ ID NO: 27; CDRL2 consisting of or comprising SEQ ID NO: 31; and CDRL3 consisting of or comprising SEQ ID NO: 37. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 5; a CDRH2 comprising or consisting of SEQ ID NO: 13; a CDRH3 comprising or consisting of SEQ ID NO: 21; a CDRL1 comprising or consisting of SEQ ID NO: 27; a CDRL2 comprising or consisting of SEQ ID NO: 31; and a CDRL3 comprising or consisting of SEQ ID NO: 38. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 7; a CDRH2 comprising or consisting of SEQ ID NO: 15; a CDRH3 comprising or consisting of SEQ ID NO: 23; a CDRL1 comprising or consisting of SEQ ID NO: 29; a CDRL2 comprising or consisting of SEQ ID NO: 30; and a CDRL3 comprising or consisting of SEQ ID NO: 40. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 5; a CDRH2 comprising or consisting of SEQ ID NO: 12; a CDRH3 comprising or consisting of SEQ ID NO: 20; a CDRL1 comprising or consisting of SEQ ID NO: 27; a CDRL2 comprising or consisting of SEQ ID NO: 31; and a CDRL3 comprising or consisting of SEQ ID NO: 38. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 7; a CDRH2 comprising or consisting of SEQ ID NO: 24; a CDRH3 comprising or consisting of SEQ ID NO: 23; a CDRL1 comprising or consisting of SEQ ID NO: 29; a CDRL2 comprising or consisting of SEQ ID NO: 30; and a CDRL3 comprising or consisting of SEQ ID NO: 40. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: comprising CDRH1 as shown in or consisting of SEQ ID NO: 5; comprising CDRH2 as shown in or consisting of SEQ ID NO: 75; comprising CDRH3 as shown in or consisting of SEQ ID NO: 20; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 37. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 5; a CDRH2 comprising or consisting of SEQ ID NO: 76; a CDRH3 comprising or consisting of SEQ ID NO: 20; a CDRL1 comprising or consisting of SEQ ID NO: 27; a CDRL2 comprising or consisting of SEQ ID NO: 31; and a CDRL3 comprising or consisting of SEQ ID NO: 37. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: A CDRH1 comprising or consisting of SEQ ID NO: 5; a CDRH2 comprising or consisting of SEQ ID NO: 12; a CDRH3 comprising or consisting of SEQ ID NO: 77; a CDRL1 comprising or consisting of SEQ ID NO: 27; a CDRL2 comprising or consisting of SEQ ID NO: 31; and a CDRL3 comprising or consisting of SEQ ID NO: 37. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises: CDRH1 comprising or consisting of SEQ ID NO: 5; CDRH1 comprising or consisting of SEQ ID NO: 12 CDRH2 consisting of the same; CDRH3 consisting of or comprising SEQ ID NO: 78; CDRL1 consisting of or comprising SEQ ID NO: 27; CDRL2 consisting of or comprising SEQ ID NO: 31; and CDRL3 consisting of or comprising SEQ ID NO: 37. According to the present invention, reference to an antibody chain comprising a specific CDR sequence (e.g., a specific CDR3 sequence) means that the specific CDR sequence forms the CDR region (e.g., CDR3 region) of the antibody chain, i.e., the CDR region consists of the specific CDR sequence, or forms part of the CDR region (e.g., CDR3 region of the antibody chain), i.e., the CDR region comprises the specific CDR sequence. In some embodiments, in the antibody or antigen-binding portion thereof, the heavy chain variable region as described above comprises any one of SEQ ID NOs: 41-46, 48-60, 79-83, or a sequence consisting of the amino acid sequence thereof, or any one of SEQ ID NOs: 41-46, 48-60, 79-83, or a sequence consisting of the amino acid sequence thereof, or a sequence having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity to the sequence of SEQ ID NOs: 41-46, 48-60, 79-83, or a sequence consisting of the amino acid sequence thereof; the light chain variable region comprises any one of SEQ ID NOs: 61-66, 68-73, or a sequence consisting of the amino acid sequence thereof, or any one of SEQ ID NOs: 61-66, 68-73, or a sequence having at least 85%, at least 90%, 91%, 92%, 93%, 94%, or at least 95%, 96%, 97%, 98%, 99% identity to the sequence of SEQ ID NOs: In some embodiments, the antibody, or antigen-binding portion thereof, comprises: (a) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 61; or (b) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 62; or (c) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 63; or (d) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 64; or (e) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 45 or 80-83 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 65; or (f) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 46 or 45 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 66; or (g) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 48 or 79 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 68; or (h) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 69; or (i) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 70; or (j) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 53 or 54 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 71; or (k) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 53-56 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 72; or (l) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 57-60 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 73. In some embodiments, the isolated antibody or antigen-binding portion thereof may comprise the variable region of the heavy chain and / or the light chain. The invention relates to a polypeptide comprising a conservative substitution or modification or replacement (e.g., conservative replacement), deletion or addition (e.g., replacement, deletion or addition of 1, 2, 3, 4 or 5 amino acids; or conservative replacement of up to 20, up to 15, up to 10, or up to 5 amino acids), or having at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100% sequence identity with the antibody or antigenic fragment thereof from which it is derived. Amino acid deletion variants comprising deletions at the N-terminus and / or C-terminus of the protein are also referred to as N-terminal and / or C-terminal truncation variants. It is understood in the art that certain conservative sequence modifications that do not eliminate antigen binding can be made. See, e.g., Brummell et al. (1993) Biochem 32:1180-8; de Wildt et al. (1997) Prot. Eng. 10:835-41; Komissarov et al. (1997) J. Biol. Chem. 272:26864-26870; Hall et al. (1992) J. Immunol. 149:1605-12; Kelley and O'Connell (1993) Biochem. 32:6862-35; Adib-Conquy et al. (1998) Int. Immunol. 10:341-6 and Beers et al. (2000) Clin. Can. Res. 6:2835-43. In some embodiments, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprising or consisting of the sequence SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or comprising or consisting of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3 comprising or consisting of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27, or comprising or consisting of the sequence KASX1HX2NX3WLA, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1 comprising or consisting of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142. Preferably, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprising or consisting of the sequence SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or comprising or consisting of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3 comprising or consisting of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27, or comprising or consisting of the sequence KASX1HX2NX3WLA, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1 comprising or consisting of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142. Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of any one of SEQ ID NOs: 12, 91-94, 119-125; (3) CDRH3 comprising or consisting of any one of SEQ ID NOs: 20, 95-97, 126-131; (4) CDRL1, which comprises or consists of any one of SEQ ID NOs: 27, 98-99, 132-135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31 or 101; (6) CDRL3, which comprises or consists of any one of SEQ ID NOs: 37, 102-104, 136-142. Preferably, the antibody comprises or consists of the CDRs shown in Table I and / or Table J, for example, comprises or consists of CDRH1, CDRH2, CDRH3 in Table I and CDRL1, CDRL2, CDRL3 in Table J. Preferably, the antibody comprises the CDRs shown in Table G or a combination thereof. Preferably, the antibody comprises or consists of the CDRs shown in Table K. In addition, the present disclosure further discloses an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the antibody or the antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises any one of SEQ ID NOs: 105-111, or a sequence consisting of thereof, or any one of SEQ ID NOs: 105-111 having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 105-111; the light chain variable region comprises SEQ ID NO: 69, or a sequence consisting of thereof, or any one of SEQ ID NOs: 69 having at least 85%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 69; or wherein the heavy chain variable region comprises SEQ ID NO: 52 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 52; and the light chain variable region comprises SEQ ID NO: 112-118 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 112-118. As described above, the term "conservative substitution / conservative replacement" as used herein refers to an amino acid substitution / replacement that does not adversely affect or change the basic properties of the protein / polypeptide comprising the amino acid sequence. For example, conservative substitution / conservative replacement can be introduced by standard techniques known in the art (e.g., site-directed mutagenesis and PCR-mediated mutagenesis). Conservative amino acid substitutions include substitutions in which an amino acid residue is replaced by another amino acid residue with a similar side chain, such as a physical or functionally similar residue (e.g., having a similar size, shape, charge, chemical properties including the ability to form covalent bonds or hydrogen bonds, etc.) to a corresponding amino acid residue. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine and histidine), amino acids with acidic side chains (e.g., aspartic acid and glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine) and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, the corresponding amino acid residue is preferably substituted by another amino acid residue from the same side chain family. Methods for identifying conservative amino acid substitutions are well known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1187 (1993); Kobayashi et al., Protein Eng. 12(10): 879-884 (1999); and Burks et al., Proc. Natl. Acad. Sci. USA 94: 412-417 (1997), which are incorporated herein by reference). According to the present invention, if reference is made to comprising a specific antibody heavy chain and / or a specific antibody light chain (e.g., chains comprising specific CDR sequences), the two heavy chains and / or the two light chains of the antibody are preferably constituted by the specific antibody heavy chain and / or the specific antibody light chain, respectively. In some embodiments, the antibody or antigen-binding portion thereof has one or more of the following properties: Binds to human or monkey CLDN6 with an EC50 of 5 μg / mL or less; Cross-reactivity: the binding properties to human CLDN3, and / or human CLDN4, and / or human CLDN9 are less than the binding properties to human CLDN6; Killing and / or inhibiting cells expressing human CLDN6 (eg, tumor cells, such as tumor cells expressing CLDN6). A unique feature of the antibodies of the invention is the ability to bind to cell surface claudin 6. This has been demonstrated by flow cytometric analysis of cells expressing claudin 6. Regardless of how the antibody is generated, methods for testing the ability of an antibody to bind to an epitope of CLDN6 are known in the art and include any antibody-antigen binding assay, such as radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, SPR, and competitive inhibition assays (see, e.g., Janeway et al., infra, and U.S. Patent Application Publication No. 2002 / 0197266 and the above section on competition assays). According to the invention, an antibody is capable of binding to a predetermined target (e.g., a CLDN6 protein or a cell expressing CLDN6) if the antibody has significant affinity for the predetermined target in a standard assay (e.g., an assay described herein). To test the binding of a monoclonal antibody to live cells expressing claudin, flow cytometry can be used. Preferably, the antibody is determined to bind to a target expressed on the cell surface in a flow cytometry analysis (FACS) analysis. If the antibody detectably binds to the target (CLDN6 protein or a cell expressing CLDN6), the antibody is capable of binding to the target and has "affinity". Preferably, an antibody in the invention detectably binds to the target if it is present at a concentration of 10 μg / mL or less, 5 μg / mL or less, 3 μg / mL or less, 2 μg / mL or less, 1 μg / mL or less, 0.5 μg / mL or less. In some embodiments, the antibody or antigen-binding portion thereof may have a binding property of: - 8 M or lower KD binds to human or monkey CLDN6; -9 M or lower KD binds to human or monkey CLDN6; 5×10 -9 M or lower KD binds to human or monkey CLDN6; or -10 Binds to human or monkey CLDN6 with a KD of M or lower. In some embodiments, the antibody or antigen-binding portion thereof may have an EC50 binding property of: binding to human CLDN6 or monkey CLDN6 with an EC50 of 5 μg / mL or less; binding to human CLDN6 or monkey CLDN6 with an EC50 of 3 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 2 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 1 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.5 μg / mL or less; binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.3 μg / mL or less; or binding to human CLDN6 or monkey CLDN6 with an EC50 of 0.1 μg / mL or less. In a standard assay, an antibody is incapable / substantially incapable of binding to a target if it does not have a significant affinity for the target and does not significantly bind to the target. Preferably, in a flow cytometry analysis (FACS analysis), wherein the binding of the antibody to the target (e.g. CLDN6 protein) expressed on the cell surface is determined, the antibody is (substantially) incapable of binding to the target if it does not detectably bind to the target. Preferably, the antibody according to the invention is present in a concentration of up to 1 μg / ml, up to 2 μg / mL, preferably up to 5 μg / mL, preferably up to 10 μg / mL, preferably up to 20 μg / mL, more preferably up to 50 μg / mL, in particular up to 100 μg / mL or up to 150 μg / mL, up to 200 μg / mL or more and does not detectably bind to the target (CLDN protein). combine. An antibody is specific for a predetermined target if it is able to bind to the predetermined target but not to other targets (i.e., has no significant affinity for other targets or does not bind significantly to other targets in standard assays). According to the invention, an antibody is specific for CLDN6 if it is able to bind to CLDN6 but not to other targets (especially claudins other than CLDN6, such as CLDN9, CLDN4, CLDN3) or binds significantly. The CLDN6 specificity described in the present invention refers to the ability to bind to one or more CLDN6 epitopes, especially CLDN6 epitopes in natural conformation, in particular human CLDN6 specificity. In some embodiments, the (b) cross-reactivity of the antibody or its antigen-binding portion may be: the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN proteins other than CLDN6; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN3 protein; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN9 protein; and / or the antibody or its antigen-binding portion does not bind or substantially does not bind to CLDN4 protein. In addition, TCGA data showed that CLDN9 was lowly expressed in the pancreas (4.23TPM, n = 4), lowly expressed in the kidney (1.99TPM, n = 25), and almost not expressed in other normal tissues (the highest expression level in the bile duct was 0.82TPM, n = 9). At the same time, CLDN9 was upregulated in ovarian cancer (5.68TPM, n = 426) and in cholangiocarcinoma (8.44TPM, n = 36). Therefore, antibodies that bind to both CLDN6 and CLDN9 can enhance the binding / inhibition of tumor cells without causing obvious toxic side effects. In some embodiments, the antibody or antigen-binding portion thereof has a strong CLDN6 binding property (e.g., the binding property that satisfies (a)) and has a certain CLDN9 binding property (e.g., the binding property to CLDN9 is 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6). An antibody or antigen-binding portion thereof having such binding properties can have a more prominent and excellent effect against tumors that widely express CLDN6 and CLDN9, such as chimeric antibodies 58G3C7, 47D5D6, 51C10H4, 20A3-2A7, 54B5A7 and improved antibodies or humanized antibodies thereof. In some embodiments, the antibody or antigen-binding portion thereof may have (b) cross-reactivity such that: the antibody or antigen-binding portion thereof does not bind or substantially does not bind to the CLDN3 protein; and / or the antibody or antigen-binding portion thereof binds to the CLDN9 protein (for example, the binding property to CLDN9 is 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6); and / or the antibody or antigen-binding portion thereof does not bind or substantially does not bind to the CLDN4 protein. In some embodiments, the antibody or its antigen-binding portion may have (b) cross-reactivity such that: the antibody or its antigen-binding portion does not bind to or substantially does not bind to CLDN3 protein; and the antibody or its antigen-binding portion binds to CLDN9 protein (for example, the binding property to CLDN9 is 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6). Such an antibody or its antigen-binding portion with such binding properties may have a more prominent and excellent effect against tumors that widely express CLDN6 and CLDN9, while avoiding cross-reactivity to tissues that widely express CLDN3 and reducing toxic side effects, such as chimeric antibodies 47D5D6, 51C10H4, 20A3-2A7, 54B5A7 and improved antibodies or humanized antibodies thereof. In some embodiments, the antibody or its antigen-binding portion has (b) cross-reactivity that: the antibody or its antigen-binding portion does not or substantially does not bind to the CLDN4 protein; and the antibody or its antigen-binding portion Partially bind to the CLDN9 protein (for example, the binding property to CLDN9 is 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6). Antibodies or antigen-binding portions thereof with such binding properties can have more prominent and excellent effects against tumors that widely express CLDN6 and CLDN9, while avoiding cross-reactivity with tissues that widely express CLDN4, and reducing toxic side effects, such as chimeric antibodies 51C10H4, 54B5A7, and improved antibodies or humanized antibodies thereof. In some embodiments, the antibody or its antigen-binding portion may have (b) cross-reactivity such that: the antibody or its antigen-binding portion does not or substantially does not bind to CLDN4 protein; and the antibody or its antigen-binding portion does not or substantially does not bind to CLDN3 protein; and the antibody or its antigen-binding portion binds to CLDN9 protein (e.g., the binding property to CLDN9 is 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6). Such an antibody or its antigen-binding portion with such binding properties may have a more prominent and excellent effect against tumors that widely express CLDN6 and CLDN9, while avoiding cross-reactivity with tissues that widely express CLDN4 and CLDN3, and avoiding / reducing toxic side effects, such as chimeric antibodies 51C10H4, 54B5A7 and improved antibodies or humanized antibodies thereof, thereby maximizing the therapeutic effect and minimizing systemic toxicity. FACS analysis revealed that the antibodies of the present invention, especially the antibodies with the above characteristics, have strong C6 reactivity (selectively bind to the surface of cells expressing CLDN6) and lower cross-reactivity. Although the antibodies of the present invention have significant CLDN6-specific binding properties, the cross-reactivity of some antibodies with CLDN3\CLDN4 unexpectedly enables some antibodies to obtain stronger and broader tumor cell killing effects. For example, studies have shown that the expression of CLDN3 and CLDN4 in several ovarian cancer cases is 83-109 times that of normal epithelial cells. In addition, DNA microarray analysis shows that CLDN3 and CLDN4 are two of the five genes with the greatest expression differences in ovarian cancer. The expression of CLDN3 and CLDN4 is abnormally increased in many ovarian cancer cases. Therefore, antibodies targeting CLDN3 / 4 or both have the potential to be used as a therapeutic method. Some antibodies have also been shown to have anti-tumor effects in preclinical animal models, and some antibodies have entered the clinical stage. For example, in the prior art, the company has screened and obtained the mouse anti-KM3900 that can recognize and bind to the second loop of CLDN4 extracellular and humanized the antibody KM3934, which exhibits antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in in vitro experiments, and can significantly inhibit tumor growth in immunodeficient mice transplanted with human ovarian cancer cell line MCAS or human pancreatic cancer cell line CFPAC-1. In some embodiments, the antibody or antigen-binding portion thereof has a strong CLDN6 binding property (for example, the binding property that satisfies (a)) and has a certain CLDN4 binding property (for example, the binding property to CLDN4 is 1 / 4 or less, 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6). Such an antibody or antigen-binding portion thereof with such binding properties can have a more prominent and excellent effect against tumors or tissues that widely express CLDN6 and CLDN4, for example, a more prominent inhibitory or killing effect in ovarian cancer cells, such as the chimeric antibodies 20A3-2A7, 47D5D6, 58G3C7, 15H2D4 and improved antibodies or humanized antibodies thereof. In some embodiments, the antibody or antigen-binding portion thereof has strong CLDN6 binding properties (e.g., the binding properties satisfying (a)) and certain CLDN3 binding properties (e.g., the binding properties to CLDN3 are 1 / 20 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less of the binding properties to CLDN6). Or lower, 1 / 200 or lower, 1 / 250 or lower), such an antibody or antigen-binding portion thereof having such binding properties can have a more prominent and excellent effect on tumors or tissues that widely express CLDN6 and CLDN3, for example, a more prominent inhibitory or killing effect in ovarian cancer cells, such as chimeric antibodies 47A5B10, 58G3C7 and improved antibodies or humanized antibodies thereof. In some embodiments, the antibody or antigen-binding portion thereof has a strong CLDN6 binding property (e.g., the binding property that satisfies (a)), has a certain CLDN3 binding property (e.g., the binding property to CLDN3 is 1 / 20 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less of the binding property to CLDN6) and has a certain CLDN4 binding property (e.g., the binding property to CLDN4 is the binding property to CLDN6 1 / 4 or less, 1 / 10 or less, 1 / 50 or less, 1 / 100 or less, 1 / 120 or less, 1 / 150 or less, 1 / 200 or less, 1 / 250 or less), such an antibody or antigen-binding portion thereof having such binding properties can have a more prominent and excellent effect against tumors or tissues that widely express CLDN6, CLDN3 and CLDN4, for example, a more prominent inhibitory or killing effect in ovarian cancer cells, such as chimeric antibodies 47A5B10, 58G3C7 and improved antibodies or humanized antibodies thereof. In some embodiments of the present invention, the antibody or antigen-binding portion thereof may have (c) killing and / or inhibiting cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) by: inducing killing and / or inhibiting cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) through antibody-dependent cell-mediated cytotoxicity (ADCC); and / or inducing killing of cells expressing human CLDN6 (e.g., tumor cells, such as tumor cells expressing CLDN6) through complement-dependent cytotoxicity (CDC). In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof competes with the aforementioned antibody or antigen-binding portion thereof for binding to CLDN6 expressed on the cell surface. In one aspect, the present disclosure provides an isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a complementarity determining region sequence of any one of SEQ ID NOs: 41-46, 48-60, 79-83 or any sequence consisting thereof and a complementarity determining region sequence of any one of SEQ ID NOs: 61-66, 68-73 or any sequence consisting thereof. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody or a humanized antibody or an improved antibody such as an improved chimeric antibody. In some embodiments, the isolated antibody or antigen-binding portion thereof comprises a constant region of IgG. The constant region of IgG is preferably selected from IgG1, IgG2, IgG3, or IgG4 constant region. The constant region of IgG is more preferably selected from the constant region of IgG1. In some embodiments, the isolated antibody, or antigen-binding portion thereof, comprises a heavy chain comprising or consisting of any sequence selected from the group consisting of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 143-167 or SEQ ID NO: 87 or SEQ ID NO: 89; and a light chain comprising or consisting of any sequence selected from the group consisting of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 168-178 or SEQ ID NO: 88 or SEQ ID NO: 90. The results show that although the antibodies of the present invention, such as 51C10H4 (composed of a heavy chain of SEQ ID NO: 87 and a light chain of SEQ ID NO: 88) and 54B5A7 (composed of a heavy chain of SEQ ID NO: 95 and a light chain of SEQ ID NO: 120) are excellent in their properties regarding binding to CLDN6 and efficacy regarding tumor treatment, respectively, We recombined the antibodies that have been obtained and verified (such as the heavy chain, light chain or CDR region of the antibody) to maintain their desired properties. For example, by recombining the heavy chain and light chain of antibodies 51C10H4 and 54B5A7, a new improved chimeric monoclonal antibody RecA101 was generated. After verification, the improved chimeric monoclonal antibody RecA101 (composed of the heavy chain of SEQ ID NO: 87 and the light chain of SEQ ID NO: 120) also has excellent properties in binding to CLDN6 and efficacy in tumor treatment. In the art, various methods are used to modify the desired properties of antibodies without changing them. In addition to the above-mentioned recombination method, amino acid replacement construction is also proven to be a feasible method in the present invention. For example, the methionine at the fifth position of the light chain CDR3 of antibody 51C10H4 is replaced with amino acid N, the V at the second position of the heavy chain CDR2 is replaced with I and the S at the tenth position is replaced with N, and the L at the tenth position of the heavy chain CDR3 is replaced with M. Such antibodies are named 54B5A7 in the present invention, which proves that they all have the desired properties, including excellent properties in binding to CLDN6 and efficacy in tumor treatment. For example, in the present invention, the sequences of the present invention, including chimeric antibody sequences or humanized antibody sequences, are subjected to conservative amino acid substitutions. For example, when the CDR region of the sequence of the present invention contains a deamidation hotspot NG (such as the CDR2 region of 20A3-2A7, the CDR2 region of 51C10H4), this site is mutated in various ways, and the mutation scheme is diverse. For example, the G in NG can be mutated to A / S / D / Q, or the N in NG can be mutated to S / Q / A to remove the amino acid that causes the risk of deamidation; for example, when the CDR region of the sequence of the present invention contains DG (such as the CDR3 region of 51C10H4), this site is mutated in various ways, and the mutation scheme is diverse. For example, the D in DG can be mutated to E / S / G, or the G can be mutated to A / S / D / Q to reduce the risk of reduced antigen binding affinity caused by isomerization. The sequences of the present invention, including chimeric antibody sequences or humanized antibody sequences, are subjected to conservative amino acid substitutions. For example, when the CDR region of the sequence of the present invention contains V (such as the CDR2 region of PiH1004), this site is mutated in various ways. The mutation scheme is diverse, for example, V can be mutated to A / I / L. Antibodies interact with target antigens primarily through amino acid residues located in the six heavy and light chain complementary determining regions (CDRs). For this reason, the amino acid sequences within the CDRs are more diverse between antibodies than sequences outside the CDRs. Since the CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of a specific naturally occurring antibody by constructing an expression vector comprising CDR sequences from the specific naturally occurring antibody grafted onto framework sequences from different antibodies with different properties (see, e.g., Riechmann, L. et al. (1998) Nature 332: 323-327; Jones, P. et al. (1986) Nature 321: 522-525; and Queen, C. et al. (1989) Proc. Natl. Acad. Sci. USA 86: 10029-10033). Such framework sequences can be obtained from public DNA databases that include germline antibody gene sequences. These germline sequences differ from mature antibody gene sequences in that they do not contain fully assembled variable genes, which are formed by V(D)J joining during B cell maturation. The germline gene sequences will also have sequences that differ from the high affinity secondary repertoire antibody at individual locations uniformly throughout the variable region. Mouse antibodies are highly immunogenic in humans, resulting in reduced therapeutic efficacy when used repeatedly, with the main immunogenicity mediated by the heavy chain constant region. If the individual antibodies are chimerized or humanized, the immunogenicity of mouse antibodies in humans can be reduced or completely avoided. Chimeric antibodies are antibodies with different parts from different animal species, for example, antibodies with variable regions from mouse antibodies and constant regions from human immunoglobulins. Chimeric antibodies are obtained by linking the variable regions of mouse antibody heavy and light chains with the constant regions of human heavy and light chains (e.g., Kraus et al., in Methods in Molecular Biology series, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8 In one preferred embodiment, a chimeric antibody is produced by connecting a human kappa light chain constant region to a mouse light chain variable region. In another preferred embodiment, a chimeric antibody can be produced by connecting a human lambda light chain constant region to a mouse light chain variable region. Humanized antibodies are antibodies in which CDR sequences / antigen-binding portions or sites derived from the germline of another mammalian species, such as a mouse, are grafted onto human framework sequences. In order to reduce the immunogenicity of the antibody to humans, the sequence of the anti-CLDN6 antibody of the present disclosure is used to produce a humanized anti-CLDN6 antibody, and the CDR region of the anti-CLDN6 antibody of mouse origin is combined with the framework region of human origin (e.g., human immunoglobulin) to form the humanized anti-CLDN6 antibody of the present disclosure. The humanized antibody is expected to retain the function of binding to human CLDN6 and the function of binding to monkey CLDN6. After humanization, 18 humanized antibody sequences with desired properties were obtained after screening (the heavy chain of any one of SEQ ID NOs: 149-160 and the heavy chain of SEQ ID NOs: NO:174-178), specifically, PiH1001, PiH1002, PiH1003, PiH1004, PiH1005, PiH1006, PiH1007, PiH1008 are humanized antibodies that meet the requirements after humanization transformation based on the chimeric antibody 51C10H4, and their CDR regions are the same as the CDR regions of 51C10H4, wherein PiH1001, PiH1002, PiH1003, PiH1004 are derived from the combination of the same light chain L3 and different heavy chains H1-H4, and wherein the humanized antibodies PiH1005, PiH1006, PiH1007, PiH1008 are derived from the combination of the same light chain L4 and different heavy chains H1-H4. Specifically, PiH2001, PiH2004, PiH2005, PiH2006, PiH2007, PiH2008, PiH2009, PiH2010, PiH2011, and PiH2012 are humanized antibodies that meet the requirements after humanization based on the chimeric antibody 54B5A7. Their CDR regions are the same as the CDR regions of 54B5A7. Among them, PiH2001 and PiH2004 are derived from the same The invention relates to a combination of a light chain L3' and different heavy chains H1' and H4', wherein PiH2005, PiH2006, PiH2007, and PiH2008 are derived from the same light chain L4' and a combination of H1', H2', H3', and H4' including the above-mentioned different heavy chains; wherein PiH2009, PiH2010, PiH2011, and PiH2012 are derived from the same light chain L5 and a combination of different heavy chains H5, H6, H7, and H8. The results show that the humanized antibodies of the present invention, compared with the corresponding chimeric antibodies before humanization, have reduced binding properties to human CLDN6 and / or monkey CLDN6 proteins, but still show excellent or conforming binding properties (such as kd binding or EC50 binding), binding to tumor cells, ADCC effect, CDC effect, and endocytosis effect. Preparation or generation of antibodies The antibodies of the present invention can be produced by a variety of techniques, including conventional monoclonal antibody methods, such as the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256: 495 (1975). Although hybridoma technology is preferred, in principle, other techniques for producing monoclonal antibodies can be used, such as virus or oncogene transformation of B lymphocytes or phage display technology using antibody gene libraries, somatic cell hybridization methods, and for example, obtaining through genetic engineering recombinant technology. For example, DNA molecules encoding the heavy chain and light chain genes of the antibodies of the present invention are obtained by chemical synthesis or PCR amplification, the resulting DNA molecules are inserted into expression vectors, and then transfected into host cells, and then, the transfected host cells are cultured under specific conditions, and the antibodies of the present invention are expressed. Other preferred animal systems for preparing hybridomas that secrete monoclonal antibodies are rat and rabbit systems (described, for example, in Spieker-Polet et al., Proc. Natl. Acad. Sci. USA 92: 9348 (1995), see also Rossie et al.. Am. J. Clin. Pathol. 124: 295 (2005)). Hybridoma production in mice is a very well established method. Immunization protocols and techniques for isolating immunized spleen cells for fusion are known in the art. Fusion partners (e.g., mouse myeloma cells) and fusion methods are also known. Monoclonal antibodies can be prepared using a variety of techniques known in the art, including hybridoma technology, recombinant technology, phage display technology, transgenic animals or some combination thereof. For example, hybridomas and biochemical and genetic engineering techniques recognized in the art can be used to produce monoclonal antibodies, as described in detail in An, Zhigiang (ed.) Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley and Sons, 1st ed.2009; Shire et al. (eds.) Current Trends in Monoclonal Antibody Development and Manufacturing, Springer Science + Business Media LLC, 1st ed.2010; Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed.1988; Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, NY, 1981), each of which is incorporated herein by reference in its entirety. It should be understood that the selected binding sequence can be further altered, for example, to increase affinity for the target, humanize the target binding sequence, improve its production in cell culture, reduce its in vivo immunogenicity, generate multispecific antibodies, etc., and antibodies comprising the altered target binding sequence are also antibodies of the present invention. In a preferred embodiment, anti-CLDN6 monoclonal antibodies are prepared by using hybridomas. In order to obtain hybridomas that produce antibodies of the invention, such as human monoclonal antibodies of the invention, spleen cells and / or lymph node cells from immunized mice can be isolated and fused to a suitable immortalized cell line, such as a mouse myeloma cell line. The resulting hybridomas are screened for the production of antigen-specific antibodies. The production of hybridomas is well known in the art. See, for example, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York. The antibodies of the present invention can also be produced in host cell transfectomas using, for example, a combination of recombinant DNA technology and gene transfection methods well known in the art (e.g., Morrison, S. (1985) Science 229: 1202). In some embodiments, DNA encoding partial or full-length light and heavy chains obtained by standard molecular biology techniques is inserted into one or more expression vectors so that the genes are operably linked to transcriptional and translational regulatory sequences. In this context, the term "operably linked" is intended to mean that the antibody gene is linked to the vector so that the transcriptional and translational control sequences within the vector perform their intended functions of regulating transcription and translation of the antibody gene. The antibody light chain gene and the antibody heavy chain gene can be inserted into the same or different expression vectors.In some embodiments, the variable region is used to produce the full-length antibody gene of any antibody isotype by inserting it into the expression vector of the heavy chain constant region and the light chain constant region encoding the desired isotype, so that the VH segment is operably connected to the CH segment and the VL segment in the carrier are operably connected to the CL segment in the carrier.In addition or alternatively, the recombinant expression vector can encode the signal peptide that promotes the secretion of the antibody chain from the host cell.The antibody chain gene can be cloned into a vector so that the signal peptide is connected to the amino terminal of the antibody chain gene.The signal peptide can be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein). To express the light and heavy chains, expression vectors encoding the heavy and light chains are transfected into host cells by standard techniques. The various forms of the term "transfection" are intended to encompass various techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, such as electroporation, calcium phosphate precipitation, DEAE-dextran transfection, etc. The antibodies of the present invention can be expressed in prokaryotic or eukaryotic host cells, such as mammalian host cells, which can assemble and secrete appropriately folded and immunologically active antibodies. Mammalian host cells for expressing the recombinant antibodies of the invention include Chinese hamster ovary cells (CHO cells) (including dhfr CHO cells described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77: 4216-4220) used with a DHFR selection marker (e.g., as described in RJ Kaufman and PA Sharp (1982) J. MoI. Biol. 159: 601-621), NSO myeloma cells, COS cells and SP2 cells. In particular, For use with NSO myeloma, another expression system is the GS gene expression system disclosed in WO 87 / 04462, WO 89 / 01036 and EP 338,841. When a recombinant expression vector encoding an antibody gene is introduced into a mammalian host cell, the antibody is produced by culturing the host cell for a period of time sufficient to allow the antibody to be expressed in the host cell or secreted into the culture medium in which the host cell is grown. The antibody can be recovered from the culture medium using standard protein purification methods. In another preferred embodiment, transgenic or transchromosomal mice carrying parts of the human immune system (rather than the mouse system) can be used to generate human monoclonal antibodies against CLDN6. Another strategy for generating monoclonal antibodies is to directly separate the gene encoding the antibody from the lymphocytes producing antibodies of the defined strategy, for example, see Babcocketal., 1996; A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined strategy. For details of recombinant antibody engineering, see Welschof and Krau, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8 and Benny KC Lo Antibody Engineering ISBN 1-58829-092-1. To prepare chimeric antibodies, murine immunoglobulin variable regions can be linked to human immunoglobulin constant regions using methods known in the art (see, e.g., U.S. Pat. No. 4,816,567 to Cabilly et al.). The isolated nucleic acid encoding the VH region can be converted into a full-length heavy chain gene by operably linking the nucleic acid encoding the VH to another DNA molecule encoding the heavy chain constant region (CH1, CH2, and CH3). The sequences of human heavy chain constant region genes are known in the art (see, e.g., Kabat et al. (1991), Sequences Of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). The heavy chain constant region can be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region, but more preferably an IgG1 or IgG4 constant region. The isolated nucleic acid encoding the VL region can be converted into a full-length light chain gene (as well as a Fab light chain gene) by operably linking the DNA encoding the VL to another DNA molecule encoding the light chain constant region CL. The sequences of human light chain constant region genes are known in the art (see, e.g., Kabat et al., supra), and DNA fragments comprising these regions can be obtained by standard PCR amplification. In a preferred embodiment, the light chain constant region can be a kappa or lambda constant region, but is generally preferably a kappa constant region. Once DNA fragments encoding VH and VL segments are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques, such as converting variable region genes into full-length antibody chain genes, Fab fragment genes, or scFv genes. In these operations, the DNA fragment encoding VL or VH is operably connected to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. The term "operably connected" as used herein is intended to indicate that two DNA fragments are connected so that the amino acid sequences encoded by the two DNA fragments remain in frame. To prepare humanized antibodies, mouse CDR regions can be inserted into human framework sequences using methods known in the art (see Winter, U.S. Pat. No. 5,225,539; Queen et al., U.S. Pat. No. 5,530,101; US Pat. No. 5,585,089; US Pat. No. 5,693,762; and Lo, Benny, KC, editor, in Antibody Engineering: Methods and Protocols, volume 248, Humana Press, New Jersey, 2004). Alternatively, transgenic animals can be used that are capable of not producing endogenous immunoglobulins after immunization and are capable of producing a complete human antibody repertoire. For example, it has been reported that homozygous deletion of the antibody heavy chain joining region (JH) gene in chimeric and germ-line mutant mice can completely suppress endogenous antibody production, and then transfer of the human germ-line immunoglobulin gene array into the germ-line mutant mice will result in the mice producing human antibodies when challenged with antigen (see, e.g., Jakobovits et al., 1993, Proc. Natl. Acad. Sci. USA 90:2551; Jakobovits et al., 1993, Nature 362:255-258; Bruggermann et al., 1993, Year in Immunology 7:33; and Duchosal et al., 1992, Nature 355:258). Non-limiting examples of the above transgenic animals include, HuMAb mice (Medarex, Inc.), which contain Human immunoglobulin gene miniloci encoding unrearranged human heavy chain (μ and γ) and κ light chain immunoglobulin sequences, plus targeted mutations that inactivate endogenous μ and κ chain loci (see, e.g., Lonberg et al. (1994) Nature 368(6474):856-859); or "KM mice TM" carrying human heavy chain transgenes and human light chain transchromosomes (see patent application WO02 / 43478). Other methods of antibody humanization include phage display technology (Hoogenboom et al., 1991, J. Mol. Biol. 227:381; Marks et al., J. Mol. Biol. 1991, 222:581-597; Vaughan et al., 1996, Nature Biotech 14:309). Nucleic acid molecules encoding the antibodies of the present invention In some aspects, the invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a heavy chain variable region and / or a light chain variable region of an isolated antibody as disclosed herein. Nucleic acids of the present invention can be obtained using standard molecular biology techniques. For hybridoma-expressed antibodies (e.g., hybridomas prepared by transgenic mice carrying human immunoglobulin genes as further described below), cDNA encoding the light and heavy chains of antibodies prepared by hybridomas can be obtained by standard PCR amplification or cDNA cloning techniques. For antibodies obtained from immunoglobulin gene libraries (e.g., using phage display technology), nucleic acids encoding such antibodies can be recovered from gene libraries. In order to prepare chimeric antibodies, methods known in the art can be used to connect the mouse immunoglobulin variable region to the human immunoglobulin constant region (see, for example, U.S. Pat. No. 4,816,567 to Cabilly et al.). The isolated nucleic acid encoding the VH region can be converted into a full-length heavy chain gene by operably connecting the nucleic acid encoding the VH to another DNA molecule encoding the heavy chain constant region (CH1, CH2 and CH3), and DNA fragments containing these regions can be obtained by standard PCR amplification. The isolated nucleic acid encoding the VL region can be converted into a full-length light chain gene (and a Fab light chain gene) by operably connecting the DNA encoding the VL to another DNA molecule encoding the light chain constant region CL. Once the DNA fragments encoding the VH and VL segments are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques, such as converting the variable region gene into a full-length antibody chain gene, a Fab fragment gene or a scFv gene. In these operations, the DNA fragment encoding VL or VH is operably connected to another DNA fragment encoding another protein, such as an antibody constant region or a flexible linker. In some embodiments, the present invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the heavy chain variable region of an isolated antibody as disclosed herein. In some embodiments, the present invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the light chain variable region of an isolated antibody as disclosed herein. In one aspect, the present disclosure provides a vector comprising the nucleic acid molecule as described above. In one aspect, the present disclosure provides a host cell comprising the nucleic acid molecule or the vector as described above. Conjugate On the one hand, the present disclosure provides a conjugate comprising an antibody or antigen-binding portion thereof as described above coupled to at least one detectable label. Detectable labels include, but are not limited to: (i) providing a detectable signal; (ii) interacting with a second label to modify the detectable signal provided by the first or second label, such as FRET (Fluorescence Resonance Energy Transfer); (iii) affecting mobility (e.g., electrophoretic mobility) by charge, hydrophobicity, shape or other physical parameters, or (iv) providing a capture portion, such as affinity, antibody / antigen or ion complexation. Structures suitable as labels include fluorescent labels, luminescent labels, chromophore labels, radioisotope labels, isotope labels, preferably stable isotope labels, isobaric labels, enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase, β-galactosidase, urease, glucose oxidase, etc.), particle labels (especially metal particle labels, magnetic particle labels, polymer particle labels), organic small molecules (e.g., biotin, ligands or binding molecules of receptors (e.g., cell adhesion proteins or lecithin), marker sequences comprising nucleic acids and / or amino acid residues that can be detected by using binding agents, etc. Labels include, but are not limited to, barium sulfate, iodine, iopanoic acid, amiopromide calcium, diatrizoate sodium, diatrizoate meglumine, meglumine, sodium tyrosine, and radiodiagnostic agents (including positron emitters, (e.g., fluorine-18 and carbon-11), gamma emitters (e.g., iodine-123, iodine-125, technetium-99m, iodine-131 and indium-111), nuclear magnetic resonance nuclides (e.g., fluorine and gadolinium)), luminescent substances (e.g., isoluminol and acridinium esters), fluorescent substances (e.g., fluorescein and rhodamine), and colored substances (e.g., latex particles and colloidal gold). Detectable labels as described above can be detected by methods known in the art. For example, radioactive labels can be detected using photographic film or scintillation counters, and fluorescent labels can be detected using photodetectors to detect emitted light. Enzyme labels are generally detected by providing a substrate to the enzyme and detecting the reaction product produced by the action of the enzyme on the substrate, and calorimetric labels are detected by simple visual coloring markers. In certain embodiments, such labels can be suitable for immunological detection (e.g., enzyme-linked immunosorbent assay, radioimmunoassay, fluorescent immunoassay, chemiluminescent immunoassay, etc.). In certain embodiments, detectable labels as described above can be connected to antibodies or antigen-binding fragments thereof of the present invention by linkers of varying lengths to reduce potential steric hindrance. Antibody Drug Conjugates / Immunoconjugates In one aspect, the present disclosure provides an antibody-drug conjugate comprising an antibody, which includes one or more drug moieties / therapeutic agents, wherein the drug moieties are directly or via a linker (e.g., covalently linked) to the antibody or antigen-binding portion thereof as described above. In the antibody-drug conjugate of the present application, the linker structure for conjugating the anti-CLDN6 antibody to the drug is not particularly limited, as long as the resulting antibody-drug conjugate can be used. Since the antibody-drug conjugate has the ability to selectively deliver one or more drugs to the target tissue (e.g., tumor-associated antigens, such as tumors expressing CLDN6 and / or CLDN9), the antibody-drug conjugate can improve the therapeutic efficacy of the antibody of the present invention or its antigen-binding portion in treating diseases (e.g., cancer). Multispecific molecules The antibodies or antigen binding portions thereof of the present invention can be used to form multispecific molecules (e.g., bispecific molecules). The antibodies or antigen binding fragments thereof of the present invention can be part of a multispecific molecule (e.g., a bispecific molecule), wherein the bispecific or multispecific molecule comprises a second functional module (e.g., a second antibody) or a third functional module (e.g., a third antibody) having a binding specificity different from that of the antibodies or antigen binding fragments thereof of the present invention, thereby being able to bind to at least two different binding sites and / or target molecules. For example, the antibodies or antigen binding fragments thereof of the present invention can be connected to a second antibody or antigen binding fragment thereof that can specifically bind to any protein that can be used as a potential target for combined therapy. To produce the bispecific or multispecific molecules, the antibodies or antigen binding fragments thereof of the present invention can be connected (e.g., by chemical coupling, genetic fusion, non-covalent association or other means) to one or more other binding molecules (e.g., additional antibodies, antibody fragments, peptides, or binding mimetics). Thus, in some aspects, the invention provides a multispecific molecule comprising an antibody or antigen-binding fragment thereof of the invention. In certain preferred embodiments, the multispecific molecule specifically binds CLDN6 (eg, human CLDN6 or monkey CLDN6) and specifically binds one or more additional targets. In certain preferred embodiments, the multispecific molecule further comprises at least one molecule having a second binding specificity for a second target (eg, a second antibody). In certain preferred embodiments, the multispecific molecule is a bispecific antibody. Chimeric Antigen Receptor (CAR) On the one hand, the present invention discloses a chimeric antigen receptor (CAR), which includes the antibody or its antigen binding portion as described above, and an immune cell activation portion, wherein the immune cell activation portion includes a transmembrane domain of an immune cell receptor and / or an intracellular signal transduction domain of an immune cell receptor. Conjugated drugs On the one hand, the present disclosure provides a targeted drug conjugate, which comprises the antibody or antigen-binding fragment thereof as described above, wherein the targeted drug conjugate is selected from radionuclide drug conjugates (RDC), wherein the radionuclide drug conjugate can be used to diagnose or treat a disease. In one aspect, the present disclosure provides an RNA drug, comprising an antibody or an antigen-binding fragment thereof as described above, wherein the RNA is selected from a nucleic acid-coupled drug, wherein the nucleic acid-coupled drug can be used to diagnose or treat a disease. The nucleic acid-coupled drug is prepared by coupling an RNA nucleic acid to an antibody or an antigen-binding fragment. On the one hand, the present disclosure provides a targeted protein degrader drug conjugate, which comprises the antibody or antigen-binding fragment thereof as described above, wherein the protein degrader drug conjugate is prepared by chemically coupling the protein degrader to the antibody or antigen-binding fragment. Pharmaceutical composition In some aspects, the present invention relates to a pharmaceutical composition. The present disclosure provides a pharmaceutical composition or a kit comprising an antibody or an antigen-binding portion thereof as described above, a nucleic acid molecule as described above, a vector as described above, a host cell as described above, a conjugate as described above, an antibody-drug conjugate as described above, a multispecific molecule as described above, or a chimeric antigen receptor as described above; and a pharmaceutically acceptable carrier. The pharmaceutical composition may optionally contain one or more additional pharmaceutically active ingredients, such as another antibody or drug. The pharmaceutical composition of the present invention may also be administered in combination with, for example, another immunostimulant, anticancer agent, antiviral agent or vaccine, so that the anti-CLDN6 antibody enhances the immune response to the vaccine. Pharmaceutically acceptable carriers may include, for example, pharmaceutically acceptable liquids, gels or solid carriers, aqueous media, non-aqueous media, antimicrobial agents, isotonic agents, buffers, antioxidants, anesthetics, suspending / dispersing agents, chelating agents, diluents, adjuvants, excipients or non-toxic auxiliary substances, combinations of various components known in the art or more. Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavoring agents, thickeners, colorants, emulsifiers or stabilizers such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, mercaptoglycerol, thioglycolic acid, mercaptosorbitol, butylmethylanisole, butylated hydroxytoluene and / or propyl arsenate. As disclosed in the present invention, in a solvent containing an antibody or its antigen-binding portion of the composition disclosed in the present invention containing one or more antioxidants such as methionine that reduce the antibody or its antigen-binding portion, it may be oxidized. Redox can prevent or reduce the reduction of binding affinity, thereby enhancing antibody stability and extending shelf life. Therefore, in some embodiments, the present invention provides a composition comprising one or more antibodies or their antigen-binding portions and one or more antioxidants such as methionine. The present invention further provides a variety of methods, wherein the antibody or its antigen-binding portion is mixed with one or more antioxidants such as methionine. Thereby, the antibody or antigen-binding portion thereof can be protected from oxidation to extend its shelf life and / or increase its activity. To further illustrate, pharmaceutically acceptable carriers may include, for example, aqueous vehicles such as sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, or dextrose and lactated Ringer's injection, non-aqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil, antimicrobial agents at bacteriostatic or fungistatic concentrations, isotonic agents such as sodium chloride or dextrose, buffers such as phosphates or citrates. Buffer, antioxidants such as sodium bisulfate, local anesthetics such as procaine hydrochloride, suspending agents and dispersants such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose or polyvinyl pyrrolidone, emulsifiers such as polysorbate 80 (TWEEN-80), isolation agents or chelating agents such as EDTA (ethylenediaminetetraacetic acid) or EGTA (ethylene glycol tetraacetic acid), ethanol, polyethylene glycol, propylene glycol, sodium hydroxide, hydrochloric acid, citric acid or lactic acid. The antimicrobial agent used as a carrier can be added to the pharmaceutical composition in the multidose container comprising phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methylparaben and propylparaben, thimerosal, benzalkonium chloride and benzethonium chloride. Suitable excipients can include for example water, saline, dextrose, glycerol or ethanol. Suitable non-toxic auxiliary substances may include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate or cyclodextrins. Administration, formulation and dosage The pharmaceutical compositions of the present invention can be administered to a subject in need thereof in vivo by various routes, including but not limited to oral, intravenous, intraarterial, subcutaneous, parenteral, intranasal, intramuscular, intracranial, intracardiac, intraventricular, intratracheal, oral, rectal, intraperitoneal, intradermal, topical, transdermal and intrathecal, or by implantation or inhalation. The compositions of the present invention can be formulated into solid, semisolid, liquid or gaseous preparations; including but not limited to tablets, capsules, powders, granules, ointments, solutions, suppositories, enemas, injections, inhalants and aerosols. Suitable preparations and routes of administration can be selected according to the intended application and treatment regimen. Suitable formulations for enteral administration include hard or soft gelatin capsules, pills, tablets (including coated tablets), elixirs, suspensions, syrups or inhalants and controlled release forms thereof. Preparations suitable for parenteral administration (e.g., by injection) include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions) in which the active ingredient is dissolved, suspended, or otherwise provided (e.g., in liposomes or other microparticles). These liquids may additionally contain other pharmaceutically acceptable ingredients, such as antioxidants, buffers, preservatives, stabilizers, bacteriostats, suspending agents, thickeners, and solutes that make the preparation isotonic with the blood (or other relevant body fluids) of the intended recipient. Examples of excipients include, for example, water, alcohol, polyols, glycerol, vegetable oils, etc. Examples of isotonic carriers suitable for such preparations include sodium chloride injection, Ringer's solution, or lactated Ringer's injection. Similarly, specific dosage regimens (including dosage, time, and repetition) will depend on specific individuals and individual medical history as well as empirical considerations such as pharmacokinetics (e.g., half-life, clearance, etc.). The requirements for effective pharmaceutical carriers for injectable formulations / compositions are well known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, JB Lippincott Company, Philadelphia, PA, eds. Banker and Chalmers, pp. 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pp. 622-630 (1986)). The frequency of administration can be determined and adjusted during the course of treatment and is based on reducing the number of proliferating or tumorigenic cells, maintaining the reduction of such tumor cells, reducing the proliferation of tumor cells or delaying the development of metastasis. In some embodiments, the dose administered can be adjusted or reduced to control potential side effects and / or toxicity. Alternatively, a sustained continuous release formulation of the therapeutic composition of the present invention may be suitable. Those skilled in the art will appreciate that appropriate dosages may vary from patient to patient. Determining the optimal dosage generally involves balancing the level of therapeutic benefit against any risks or deleterious side effects. The dosage level selected will depend on a variety of factors, including, but not limited to, the activity of the particular compound, administration, time of administration, rate of compound clearance, duration of treatment, other drugs, compounds and / or materials used in combination, severity of the condition, and the species, sex, age, weight, condition, general health and previous medical history of the patient. The amount of compound and route of administration are ultimately determined by the physician, veterinarian or clinician, but the dosage is generally selected to achieve a local concentration at the site of action that achieves the desired effect, without Causes substantial harmful or adverse side effects. Generally, the antibodies of the present invention or their antigen-binding portions can be administered in various ranges. These include about 5 μg / kg body weight to about 100 mg / kg body weight per dose; about 50 μg / kg body weight to about 5 mg / kg body weight per dose; about 100 μg / kg body weight to about 10 mg / kg body weight per dose. Other ranges include about 100 μg / kg body weight to about 20 mg / kg body weight per dose and about 0.5 mg / kg body weight to about 20 mg / kg body weight per dose. In certain embodiments, the dosage is at least about 100 μg / kg body weight, at least about 250 μg / kg body weight, at least about 750 μg / kg body weight, at least about 3 mg / kg body weight, at least about 5 mg / kg body weight, at least about 10 mg / kg body weight. In any case, the antibodies or antigen-binding portions thereof of the present invention are preferably administered to subjects in need as needed. The frequency of administration can be determined by those skilled in the art, such as the attending physician based on the considerations of the condition being treated, the age of the subject being treated, the severity of the condition being treated, the general health of the subject being treated, etc. In certain preferred embodiments, the course of treatment involving the antibodies or antigen-binding portions thereof of the invention will include multiple doses of the selected pharmaceutical product administered over a period of weeks or months. More specifically, the antibodies or antigen-binding portions thereof of the invention may be administered every day, every two days, every four days, every week, every ten days, every two weeks, every three weeks, every month, every six weeks, every two months, every ten weeks or every three months. In this regard, it will be appreciated that the dosage may be changed or the interval adjusted based on patient response and clinical practice. The dosage and regimen of the disclosed therapeutic composition can also be determined empirically in individuals given one or more administrations. For example, an individual may be given incremental doses of a therapeutic composition produced as described herein. In selected embodiments, the dosage may be gradually increased or decreased or mitigated, respectively, based on empirically determined or observed side effects or toxicity. In order to assess the efficacy of the selected composition, markers of a specific disease, disorder or condition may be tracked as described above. For cancer, these include direct measurement of tumor size by palpation or visual observation, indirect measurement of tumor size by X-ray or other imaging techniques; improvements assessed by direct tumor biopsy and microscopic examination of tumor specimens; measurement of indirect tumor markers (e.g., PSA for prostate cancer) or tumorigenic antigens identified according to the methods described herein, relief of pain or paralysis; improvements in speech, vision, breathing or other disabilities associated with the tumor; increased appetite; or improvements in quality of life or prolonged survival as measured by accepted tests. Those skilled in the art will appreciate that the dosage will vary depending on the individual, the type of tumor condition, the stage of the tumor condition, whether the tumor condition has begun to metastasize to other locations in the individual, and the treatments used in the past and the treatments used concurrently. Compatible formulations for parenteral administration (e.g., intravenous injection) will include an antibody or antigen-binding portion thereof as disclosed herein at a concentration of about 10 μg / mL to about 100 mg / mL. In certain selected embodiments, the concentration of the antibody or antigen-binding portion thereof will include 20 μg / mL, 40 μg / mL, 60 μg / mL, 80 μg / mL, 100 μg / mL, 200 μg / mL, 300 μg / μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, 800 μg / mL, 900 μg / mL or 1 mg / mL. In other preferred embodiments, the ADC concentration will include 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 8 mg / mL, 10 mg / mL, 12 mg / mL, 14 mg ml, 16 mg / mL, 18 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL or 100 mg / mL. The antibodies of the present invention can be co-administered with one or more other therapeutic agents (e.g., cytotoxic agents, radiotoxic agents, anti-tumor agents, anti-angiogenic agents, or immunosuppressants) to reduce the induction of an immune response against the antibodies of the present invention. The antibody can be linked to the therapeutic agent (as an immune complex) or can be administered separately from the therapeutic agent. In the case of separate administration, the antibody can be administered before, after, or simultaneously with the therapeutic agent, or can be co-administered with other known treatments (e.g., anti-cancer treatments (e.g., radiotherapy, chemotherapy)). In the context of administering a treatment, the term "combination" or "co-administration" as used herein refers to the use of more than one treatment or therapeutic agent. The use of the term "combination" does not limit the order in which the treatment or therapeutic agent is administered to a subject. The treatment or therapeutic agent may be administered before, simultaneously, or after the second treatment or therapeutic agent is administered to the patient. Preferably, the treatment or therapeutic agent is administered to the subject in a certain order, amount, and / or within a certain time interval so that the treatment or therapeutic agent can work together. In a specific embodiment, the treatment or therapeutic agent is administered to the subject in a certain order, amount, and / or within a certain time interval so that they provide an increased benefit than if they were administered in other ways (particularly independently of each other). Preferably, the increased benefit is a synergistic effect. Medical Uses The antibodies, antibody compositions and methods of the invention have many in vitro and in vivo uses, including, for example, detection of CLDN6 or enhancement of immune responses. For example, these molecules can be administered to cultured cells in vitro or ex vivo, or, for example, administered to human subjects in vivo. Preferred subjects include mammals, such as humans / patients in need. Mammals in the context of the present invention are humans, non-human primates, domesticated animals such as dogs, cats, sheep, cows, goats, pigs, horses, etc., laboratory animals such as mice, rats, rabbits, guinea pigs, etc., and captive animals, such as zoo animals. The present invention further provides a method for detecting the presence of a human CLDN6 antigen in a sample or measuring the amount of a human CLDN6 antigen, comprising contacting a sample and a control sample with a monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CLDN6 under conditions that allow formation of a complex between the antibody or a portion thereof and human CLDN6. The formation of the complex is then detected, wherein differential complex formation between the samples compared to the control sample indicates the presence of a human CLDN6 antigen in the sample. In addition, the anti-CLDN6 antibodies of the present invention can be used to purify human CLDN6 by immunoaffinity purification. In some embodiments, the sample comprises a cell. Treating medical conditions including cancer In some aspects, the invention provides a method of treating a disorder in a mammal, comprising administering a therapeutically effective amount of an antibody or antigen-binding portion thereof disclosed herein to a subject (eg, a human) in need of treatment. For example, the disorder is cancer. In some aspects, the antibodies disclosed herein have one or more of the following activities: (i) killing cells expressing CLDN6; (ii) inhibiting the proliferation of cells expressing CLDN6; (iii) inhibiting colony formation of cells expressing CLDN6; (iv) mediating tumor remission (e.g., volume reduction), preferably complete remission (e.g., complete disappearance); (v) preventing tumor formation or re-formation, and (vi) inhibiting the metastasis of cells expressing CLDN6. Therefore, the antibodies can be used for one or more of the aforementioned (especially when administered to a patient). As described herein, the antibodies disclosed herein have one or more activities that can be therapeutically applied to kill cells and / or inhibit cells. In particular, killing cells, inhibiting the proliferation of cells and / or inhibiting the colony formation of cells can be used to treat or prevent cancer (including cancer metastasis). Inhibiting the proliferation, colony formation and / or metastasis of cells can be applied, especially for treating or preventing cancer metastasis and metastatic spread of cancer cells. In some aspects, the antibodies of the present disclosure mediate killing of cells (e.g., cells expressing human CLDN6, such as tumor cells, or tumor cells expressing CLDN6) by inducing antibody-dependent cellular cytotoxicity (ADCC)-mediated lysis, apoptosis, homophilic adhesion and / or phagocytosis. In some aspects, the antibodies of the present disclosure mediate killing of cells (e.g., cells expressing human CLDN6, such as tumor cells, or tumor cells expressing CLDN6) by inducing complement-dependent cytotoxicity (CDC)-mediated lysis, apoptosis, homotypic adhesion and / or phagocytosis. However, the present disclosure also includes some embodiments in which the antibodies exert the activities described herein. (e.g., killing cells and / or inhibiting one or more cellular activities (e.g., cell proliferation and / or colony formation) without inducing complement dependent cytotoxicity (CDC)-mediated lysis, antibody dependent cellular cytotoxicity (ADCC)-mediated lysis, apoptosis, homotypic adhesion and / or phagocytosis. The antibodies of the invention may interact with components of the immune system, preferably via ADCC or CDC. Furthermore, the antibodies of the invention may also act by simply binding to CLDN6 on the surface of a cell (thus, for example, blocking the proliferation of the cell). In some aspects, ADCC-mediated cell lysis occurs in the presence of effector cells, and in some specific embodiments, the effector cells are selected from monocytes, mononuclear cells, NK cells, and neutrophils (PMNs). In some specific embodiments, phagocytosis is performed by macrophages. In some aspects, the antibodies of the present disclosure exhibit one or more immune effector functions on cells bearing CLDN6, particularly CLDN6 in a native conformation, wherein the one or more immune effector functions are preferably selected from complement dependent cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity (ADCC), induction of apoptosis, and inhibition of proliferation. The antibodies of the invention may interact with components of the immune system, preferably via ADCC or CDC. Furthermore, the antibodies of the invention may also act by simply binding to CLDN6 on the surface of a cell (thus, for example, blocking the proliferation of the cell). In some aspects, the present disclosure provides a method for treating a disease related to CLDN6 expression and / or CLDN6 binding to its cell surface or determining its prognosis in a subject, comprising administering an effective dose of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit to a subject in need thereof. In some aspects, the present disclosure provides the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit for use in a method for treating a disease associated with CLDN6 expression or binding of CLDN6 to its cell surface or determining its prognosis in a subject. In some aspects, the present disclosure provides use of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit in the preparation of an agent for treating a disease associated with CLDN6 expression or determining the prognosis thereof. According to the present invention, "diseases associated with CLDN6 expression and characterized by binding of CLDN6 to its cell surface" means that the expression and binding of CLDN6 in cells of pathological tissues or organs are preferably increased compared to the state in healthy tissues or organs. Increase refers to an increase of at least 10%, in particular at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, at least 1000%, at least 10000% or even higher; or increase refers to the detection of the indicator from nothing to something, and thereafter, optionally including the increase in the above-mentioned numerical range. In one embodiment, expression and binding to the cell surface are only found in pathological tissues, while expression in healthy tissues is suppressed. According to the present invention, diseases associated with CLDN6 expression and characterized by binding of CLDN6 to its cell surface include tumor diseases, such as cancer. In addition, according to the present invention, tumor diseases (such as cancer) are preferably such diseases in which tumor cells or cancer cells express CLDN6 and are characterized by binding of CLDN6 to their cell surface. The methods provided by the present disclosure can be used to treat or prevent various cancers involving CLDN6, whether malignant or benign, and whether primary or secondary. The cancer can be a solid cancer or a hematological malignancy. Examples of such cancers include lung cancers such as bronchial cancers (e.g., squamous cell carcinoma, small cell carcinoma, large cell carcinoma, and adenocarcinoma), alveolar cell carcinoma, bronchial adenoma, cartilaginous hamartoma (noncancerous), and sarcoma (cancerous); heart cancers such as myxoma, fibroma, and rhabdomyoma; bone cancers such as osteochondroma, condromas, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, giant cell tumor, chondrosarcoma, multiple myeloma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, Ewing's tumor (Ewing's sarcoma), and reticulum cell sarcoma; brain cancers such as gliomas (e.g., glioblastoma multiforme), anaplastic astrocytoma, , astrocytoma, oligodendroglioma, medulloblastoma, chordoma, neurilemoma, ependymoma, meningioma, pituitary adenoma, pinealoma, osteoma, hemangioblastoma, craniopharyngioma, chordoma, germ cell tumor, teratoma, dermoid cyst and hemangioma; cancers of the digestive system such as colon cancer, leiomyoma, epidermoid carcinoma, adenocarcinoma, leiomyosarcoma, gastric adenocarcinoma, intestinal lipoma, intestinal neurofibroma, intestinal fibroma, colorectal polyp and colorectal cancer; liver cancer such as hepatocellular adenoma, hemangioma, hepatocellular carcinoma, fibrocarcinoma, bile duct cancer, hepatoblastoma and angiosarcoma; kidney cancer such as renal adenocarcinoma, renal cell carcinoma, adrenal tumor and transitional cell carcinoma of the renal pelvis; bladder cancer; blood liquid cancers such as acute lymphocytic (lymphoblastic) leukemia, acute myeloid (myelocytic, myeloid, myeloblastic, myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., Sezary syndrome and hairy cell leukemia), chronic myeloid (myeloid, myeloid, granulocytic) lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, mycosis fungoides, and myeloproliferative disorders (including myeloproliferative disorders such as polycythemia vera, myelofibrosis, thrombocythemia, and chronic myelogenous leukemia); skin cancers such as basal cell carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, and Paget's disease; head cancers such as basal cell carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, and Paget's disease; Cancers of the cervix, ovaries, ovaries, ovaries, uterus, vagina, fallopian tubes, and hydatidiform moles are also included in the invention. Cancers of the cervix, ovaries ... In some embodiments, the disease associated with CLDN6 expression is cancer, and the cancer is preferably selected from the group consisting of ovarian cancer (e.g., ovarian adenocarcinoma and ovarian teratoma), lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), gastric cancer, breast cancer, liver cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, bladder cancer, kidney cancer, colorectal cancer, small intestine cancer, placental choriocarcinoma, cervical cancer, testicular cancer (e.g., testicular teratoma and embryonic testicular cancer) and uterine cancer and metastatic forms thereof. In some embodiments, the disease associated with CLDN6 expression is a fibrotic disease or a fibrosis-driven cancer, and the fibrosis-related disease includes a disease caused by fibrosis, a disease manifested as fibrosis, or a complication caused by fibrosis. In some embodiments, the fibrotic disease is selected from fibrosis of the lung, liver, colon, gallbladder, or stomach. In some embodiments, the fibrotic disease is selected from the group consisting of hepatitis, pulmonary fibrosis, liver fibrosis, cirrhosis, scleroderma, and biliary atresia. In some embodiments, the hepatitis comprises non-alcoholic steatohepatitis (NASH). In some embodiments, the pulmonary fibrosis comprises idiopathic pulmonary fibrosis. In some embodiments, the liver fibrosis includes alcohol- or drug-induced liver fibrosis, infection-induced liver fibrosis. According to the present invention, the terms "fibrosis" and "fibrotic diseases" refer to the excessive growth of fibrous connective tissue in organs or tissues. More specifically, fibrosis is a pathological process that involves persistent fibrotic scarring and excessive production of extracellular matrix by connective tissue in response to tissue injury. Physiologically, deposits of connective tissue can destroy the architecture and function of an organ or tissue. The inventors evaluated the antibody action and effect in liver fibrosis models (such as long-term CDAA diet-induced liver fibrosis model, CCl4-induced liver injury model, etc.), and found through immunohistochemical staining that the antibody of the present invention can reduce liver fibrosis. The inventors also found that the antibodies of the present invention have beneficial effects in treating biliary atresia by observing indicators such as mouse body weight, survival rate, degree of liver tissue damage and fibrosis, and cytokines closely related to fibrosis in a biliary atresia mouse model (e.g., an RRV-induced biliary atresia mouse model). The antibodies, or antigen-binding portions thereof, can be used alone as a monotherapy or can be used in combination with chemotherapy or radiation therapy. The antibodies, or antigen-binding portions thereof, can be used in combination with anti-cancer agents, cytotoxic agents, or chemotherapeutic agents. The term "metastasis" means that cancer cells spread to other parts of the body from its initial position. The formation of metastasis is a very complicated process, which depends on the malignant cells to break away from the primary tumor, invade the extracellular matrix, penetrate the endothelial basement membrane to enter the body cavity and blood vessels, and then transport by blood, and then infiltrate the target organ. Finally, the growth of new tumors in the target position depends on angiogenesis. Even after removing the primary tumor, tumor metastasis often occurs, because tumor cells or components can remain and develop metastasis potential. In one embodiment, term "metastasis" according to the present invention means "distant metastasis", which means the metastasis away from the primary tumor and the local lymph node system. The cells of a secondary or metastatic tumor are similar to those in the primary tumor. This means, for example, that if ovarian cancer metastasizes to the liver, the secondary tumor is made up of abnormal ovarian cells (rather than abnormal liver cells), and the tumor in the liver is called metastatic ovarian cancer (rather than liver cancer). The term "anticancer agent" or "antiproliferative agent" means any agent that can be used to treat a cell proliferative disorder such as cancer, and includes, but is not limited to, cytotoxic agents, cytostatic agents, anti-angiogenic agents, radiotherapy and radiotherapeutic agents, targeted anticancer agents, BRMs, therapeutic antibodies, cancer vaccines, cytokines, hormone therapy, radiotherapy, anti-metastatic agents, and immunotherapeutic agents. It should be understood that in selected embodiments as described above, such anticancer agents may comprise a conjugate and may be combined with the disclosed site-specific antibodies prior to administration. More specifically, in certain embodiments, the selected anticancer agent is linked to an unpaired cysteine of an engineered antibody to provide an engineered conjugate as described herein. Therefore, such an engineered conjugate is explicitly contemplated within the scope of the present invention. In other embodiments, the disclosed anticancer agent will be administered in combination with a site-specific conjugate comprising a different therapeutic agent as described above. The present invention also provides a combination of an antibody or an antigen-binding portion thereof with radiotherapy (i.e., any mechanism for inducing DNA damage locally in tumor cells, such as γ-irradiation, X-rays, UV-irradiation, microwaves, electron emission, etc.). Combination therapy using directed delivery of radioisotopes to tumor cells is also contemplated, and the disclosed conjugates can be used in combination with targeted anticancer agents or other targeted means. Typically, radiotherapy is administered in a pulsed manner over a period of about 1 week to about 2 weeks. Radiotherapy can be administered to subjects with head and neck cancer for about 6 to 7 weeks. Optionally, radiotherapy can be administered as a single dose or as multiple sequential doses. diagnosis The present invention provides in vitro and in vivo methods for detecting, diagnosing or monitoring proliferative disorders and methods for screening cells from patients to identify tumor cells, including tumorigenic cells. Such methods include identifying individuals with cancer for treatment or monitoring the progression of cancer, comprising contacting a patient or a sample obtained from a patient (in vivo or in vitro) with an antibody as described herein, and detecting the presence or absence of an antibody that binds to a bound or free target molecule in the sample or Binding Levels. In some embodiments, the antibody will comprise a detectable label or reporter molecule as described herein. In some aspects, the present disclosure provides a method for diagnosing, detecting or monitoring a disease associated with CLDN6 expression, comprising administering an effective dose of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit to a subject in need thereof. In some aspects, the present disclosure provides the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit for use in a method for diagnosing, detecting or monitoring a disease associated with CLDN6 expression in a subject. In another aspect, the present disclosure provides use of the antibody or antigen-binding portion thereof, the nucleic acid molecule, the vector, the host cell, the conjugate, the antibody-drug conjugate, the multispecific molecule, the chimeric antigen receptor, or the pharmaceutical composition or kit in the preparation of an agent for diagnosing, detecting or monitoring a disease characterized by expression of CLDN6 or binding of CLDN6 to its cell surface. In some embodiments, binding of an antibody to specific cells in a sample can indicate that the sample is likely to contain tumorigenic cells, thereby indicating that an individual with cancer can be effectively treated with an antibody described herein. Samples can be analyzed by a variety of assays, such as radioimmunoassays, enzyme immunoassays (e.g., ELISA), competitive binding assays, fluorescent immunoassays, immunoblotting assays, Western blot analysis, and flow cytometry assays. Compatible in vivo diagnostics or diagnostic assays can include imaging or monitoring techniques known in the art, such as magnetic resonance imaging, computerized tomography (e.g., CAT scans), positron emission tomography (e.g., PET scans), radiography, ultrasound, etc., known to those skilled in the art. The method for detecting or monitoring CLDN6 expression or the level of cells expressing CLDN6 in vitro described in the present invention can also be used for non-diagnostic purposes. Preferred subjects include mammals, such as humans / patients in need thereof. The sample from the subject is blood, excreta (urine or feces), oral or nasal secretions, or alveolar lavage fluid, tissue fluid, sweat, or extracts thereof from the subject. Pharmaceutical packaging and kits Also provided are pharmaceutical packaging and kits containing one or more containers of one or more doses of an antibody or an antigen-binding portion thereof. In certain embodiments, a unit dose is provided, wherein the unit dose contains a predetermined amount of a composition comprising, for example, an antibody or an antigen-binding portion thereof, with or without one or more other agents. For other embodiments, such a unit dose is supplied in a disposable prefilled syringe for injection. In other embodiments, the composition contained in the unit dose may contain saline, sucrose or the like; a buffer such as phosphate, etc.; and / or be formulated in a stable and effective pH range. Alternatively, in certain embodiments, the conjugate composition may be provided as a lyophilized powder, which may be reconstituted after adding a suitable liquid (e.g., sterile water or saline solution). In certain preferred embodiments, the composition comprises one or more substances that inhibit protein aggregation, including but not limited to sucrose and arginine. Any label on or associated with the container indicates that the encapsulated conjugate composition is used to treat a selected tumor disease condition. The present invention also provides a kit for producing a single-dose or multi-dose administration unit of a site-specific conjugate and, optionally, one or more anticancer agents. The kit includes a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, and the like. The container can be formed of a variety of materials, such as glass or plastic, and contains a pharmaceutically effective amount of the disclosed conjugate in conjugated or unconjugated form. In other preferred In an embodiment, the container includes a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). Such a kit typically contains a pharmaceutically acceptable formulation of an engineered conjugate in a suitable container, and optionally contains one or more anticancer agents in the same or different containers. The kit may also contain other pharmaceutically acceptable formulations for diagnosis or combined therapy. For example, in addition to the antibody or antigen-binding portion thereof of the present invention, such a kit may contain any one or more anticancer agents, such as chemotherapeutic agents or radiotherapeutic agents; anti-angiogenic agents; anti-metastatic agents; targeted anticancer agents; cytotoxic agents; and / or other anticancer agents. More specifically, the kit can have a single container containing the disclosed antibody or antigen-binding portion thereof, with or without additional components, or they can have different containers for each required reagent. In the case of providing a combination therapeutic agent for conjugation, a single solution can be premixed in a molar equivalent combination or one component more than another. Alternatively, the conjugate of the kit and any optional anticancer agent can be stored separately in different containers before being administered to the patient. The kit can also include a second / third container device for containing a sterile pharmaceutically acceptable buffer or other diluent such as antibacterial water for injection (BWFI), phosphate buffered saline (PBS), Ringer's solution and glucose solution. When the components of the kit are provided in one or more liquid solutions, the liquid solution is preferably an aqueous solution, particularly preferably a sterile aqueous solution or a saline solution. However, the components of the kit may be provided as dry powders. When the reagents or components are provided in dry powder form, the powder may be reconstituted by adding a suitable solvent. It is contemplated that the solvent may also be provided in another container. As briefly described above, the kit may also contain a means for administering the antibody or antigen-binding portion thereof and any optional components to a patient, such as one or more needles, IV bags or syringes, or even eye drops, pipettes or other similar devices, by which the formulation can be injected or introduced into an animal or applied to a diseased area of the body. The kit of the invention will typically also include a device for containing vials or the like and other tightly closed components for commercial sale, such as an injection or blow molded plastic container, in which the desired vials and other devices are placed and retained. This application is accompanied by a sequence listing containing a number of nucleic acid and amino acid sequences. Tables A, B, C and D, E and F below provide an overview of the sequences contained. An illustrative antibody as disclosed herein is an anti-CLDN6 monoclonal antibody. Table A. CDR amino acid sequences Table B. Variable region amino acid sequences Table C. CDR amino acid sequences of improved antibodies Table D. Variable region amino acid sequences of improved antibodies Table E. IgG1 heavy chain constant region, IgG1 light chain constant region, signal peptide used in the full-length sequence Table F. Various full-length sequences of 51C10H4 as examples Table G. CDR amino acid sequences of improved antibodies Table H. Variable region sequences of improved antibodies Example The invention generally described herein will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the invention. These examples are not intended to represent that the experiments below are all or the only experiments performed. Example 1. Preparation of materials 1.1 Generation of immunogens Immunogens used in the present disclosure include plasmid DNA and stable cell lines. 1.1.1 Preparation of gene immunization bullets. The DNA sequence of human CLDN6 was cloned into the plasmid pCDH-CMV-MCS-EF1-Puro, and the plasmid pCDH-CMV-MCS-EF1-Pur-CLDN6 was transformed into the cloning strain Stbl3. The plasmid was amplified at 30°C, and the plasmid DNA was extracted by conventional methods. Gene immunization bullets were prepared using Bio-rad gold particles and pCDH-CMV-MCS-EF1-Pur-CLDN6 plasmid. Each gene immunization bullet contained approximately 3 μg of plasmid DNA. 1.1.2 The DNA sequence of human CLDN6 was cloned into plasmid pcDNA3.4, and the target gene plasmid was transfected into CHO-K1 cells. The stable cell line CHO-K1-CLDN6 expressing the target protein CLDN6 was constructed by screening. 1.2 Production of benchmark antibodies In the examples, a reference antibody, IMAB027, was used as a positive control. The variable region sequence of mAb206-LCC according to U.S. Pat. No. 14 / 117118 (CN103748112B) (see SEQ ID NO: 47 and SEQ ID NO: 67 in Table B) was linked to the human IgG1 constant region sequence (see SEQ ID NO: 84 and SEQ ID NO: 85 in Table E), and the code name was IMAB027. In the examples, a reference antibody, AB3-7, was also used as a positive control. The variable region sequence of antibody 3-7 in Table D of Chinese patent CN114174340A (see SEQ ID NO: 387 and SEQ ID NO: 389 in Table D) was connected with the constant region sequence of human IgG1 (see SEQ ID NO: 84 and SEQ ID NO: 85 in Table E), and the code name was AB3-7. 1.3 Establishment of stable cell lines Human CLDN6, mouse CLDN6 (Mouse CLDN6), monkey CLDN6 (Cyno CLDN6), human CLDN3, human CLDN4, and human CLDN9 were overexpressed in HEK293T cells and CHO-K1 cells respectively by lentiviral infection. Antibiotics were added 72 hours after cell infection and cultured for 2-4 weeks. Single clones were picked, amplified, and frozen to obtain 8 cell lines, including HEK293T-CLDN6, HEK293T-CLDN9, HEK293T-CLDN3, HEK293T-CLDN4, CHO-K1-CLDN9, CHO-K1-CLDN6, CHO-K1-Mouse CLDN6, and CHO-K1-Cyno CLDN6, for subsequent animal immunization and screening. Example 2. Production of antibodies 2.1 Immunization and cell fusion 2.1.1 Immunity On days 0 and 20, 3 μg of plasmid DNA containing CLDN6 was intraperitoneally injected into Balb / c mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.). On days 40, 54, 63, and 83, CHO-K1 cells transfected with pcDNA3.4-CLDN6 were injected at a concentration of 5×10 6 / ml, 0.5mL was injected intraperitoneally to immunize Balb / c mice. According to the immunization process, submandibular venous blood of immunized mice was collected on days 47 and 70 for serum titer detection. Serum titer was identified by FACS method, and animals with higher serum titer were selected for spleen cell fusion. Three days before spleen cell fusion, mice showing the highest antibody titer received booster immunization. 2.1.2 Cell fusion The spleens of mice that had been immunized multiple times were extracted and homogenized to produce single-cell suspensions. At the same time, myeloma cell (SP2 / 0) single-cell suspensions were prepared. Approximately 8×10 7The spleen cells were electrofused with SP2 / 0 mouse myeloma cells. The fused cells were resuspended in HAT medium (DMEM / 10% FBS medium containing hypoxantine, aminopterin and thymidin) containing hybridoma cell selection agents and transferred to a 96-well cell culture plate. The cells were incubated at 37°C in 5.5% CO2. After 6-7 days of incubation, fused hybridoma cells that can express antibodies and proliferate indefinitely in vitro were obtained, which are called hybridoma mother cells. The ability of hybridoma cell supernatants to express antibodies and bind to CLDN6 was detected using FACS. 2.2 Screening of hybridoma supernatants The hybridoma supernatant was subjected to flow cytometry screening. Using HEK293T-CLDN6, a positive cell overexpressing CLDN6, hybridoma supernatants with specific binding to CLDN6 were identified by FACS analysis. HEK293T-CLDN9, HEK293T-CLDN3, HEK293T-CLDN4, and HEK293T were used for negative screening. The hybridoma supernatant can be used to inoculate the antibody-secreting hybridoma again into DMEM / 10% FBS medium for secondary screening to obtain monoclonal hybridomas. 2.3 Hybridoma Sequencing After screening, hybridoma monoclones that can specifically bind to CLDN6-overexpressing cells and tumor cells that naturally express CLDN6 were obtained and sequenced. The variable regions of the hybridoma monoclones were obtained using NGS sequencing. NGS sequencing method: Extract RNA from hybridoma cells, reverse transcribe it into cDNA, and amplify IgG with antibody primers. Add a unique tag sequence (index sequence) to each hybridoma antibody gene. Mix all gene samples and sequence them on an NGS sequencer. Use bioinformatics to analyze the sequencing results, split the IgG sequence, and then restore the cell lines from which these sequences originated through the index sequence. 2.4 Chimeric antibodies Chimerization of antibodies is achieved by linking the variable regions of murine antibody heavy and light chains to human heavy and light chain constant regions (e.g., as described by Kraus et al. in Methods in Molecular Biology series, Recombinant antibodies for cancer therapy ISBN-0-89603-918-8, or as described in CN 111875703 A,
[0313] part). In the present disclosure, the variable regions of the heavy and light chains of the murine antibody (see Table B) are connected to the human IgG1 heavy and light chain constant regions (see Table E) to obtain the full-length sequence of the chimeric antibody (e.g., Table F). It should be understood by those skilled in the art that the heavy chain constant region used to generate the chimeric antibody can be IgG1, IgG3, IgG4, IgG2, IgA, IgD or IgM. The full-length sequence of the antibody of the present invention can be obtained by connecting the corresponding variable region and the constant region of human IgG, such as IgG1, IgG2, IgG3, and IgG4 constant regions. Specifically, as an example, the heavy chain variable region of each antibody (including a chimeric antibody, a humanized antibody, or an improved antibody) is connected to the IgG1 heavy chain constant region to obtain the full-length sequence of the heavy chain of the antibody, and further, a signal peptide can be connected to the other end of the heavy chain variable region to obtain a full-length sequence containing the signal peptide; as an example, the light chain variable region of each antibody (including a chimeric antibody, a humanized antibody, or an improved antibody) is connected to the IgG1 light chain constant region to obtain the full-length sequence of the light chain of the antibody, and further, a signal peptide can be connected to the other end of the light chain variable region to obtain a full-length sequence containing the signal peptide. Among them, the amino acid sequences of the IgG1 heavy chain constant region, IgG1 light chain constant region, and signal peptide described in the present invention are shown in Table E. As an example, the full-length sequence of the heavy chain of 51C10H4, the full-length sequence of the heavy chain including the signal peptide, the full-length sequence of the light chain of 51C10H4, and the full-length sequence of the light chain including the signal peptide are described in Table F. Combining the construction of the above-mentioned full-length sequences of the present invention and the examples in Table F, the full-length sequences of all chimeric antibodies, improved antibodies / improved antibodies, and humanized antibodies of the present invention can be obtained. For example, as described above, the full-length sequence of the humanized antibody can be obtained in the same manner, by connecting the variable region of the humanized antibody in Table B with the IgG1 constant region in Table E. Specifically, the heavy chain variable region of the humanized antibody is connected to the IgG1 heavy chain constant region to obtain the full-length sequence of the heavy chain of the humanized antibody. Further, a signal peptide can be connected to the other end of the heavy chain variable region to obtain the full-length sequence including the signal peptide. Specifically, the light chain variable region of the humanized antibody is connected to the IgG1 light chain constant region to obtain the full-length sequence of the light chain of the humanized antibody. Further, a signal peptide can be connected to the other end of the light chain variable region to obtain the full-length sequence including the signal peptide. 24 hours before transfection, culture Expi293F cells normally. During transfection, dilute Expi293F cells to 3×10 6 / mL, add preheated OptiPRO medium to two centrifuge tubes. Add heavy chain plasmid and light chain plasmid to one centrifuge tube, and then add transfection reagent to the other centrifuge tube, and immediately mix at room temperature to obtain a complex. Incubate at room temperature for 1-2 minutes. Add the complex to the normally cultured Expi293F cells, continue to culture in a shaker at 37°C and 8% CO2 for 18-22 hours, and then add the transfection enhancer and cell culture medium to the cells. Then place the cells in a shaker at 32°C and 5% CO2 for further culture. On the fourth day of transfection, add cell culture medium to the cells, and continue to culture the cells in a shaker at 32°C and 5% CO2. Harvest the supernatant in the culture flask on the 9th day of transfection and perform affinity purification using a protein A column. The CLDN6 antibody of the present invention is a four-transmembrane protein with four transmembrane hydrophobic regions and two extracellular regions. Its recombinant protein is extremely difficult to express, so it is difficult to prepare a suitable protein antigen for CLDN6 antibody for immunization and screening. In addition, due to the high homology of the amino acid sequence of CLDN6 and its family members such as CLDN9, CLDN3 and CLDN4, it is quite difficult to screen out monoclonal antibodies that specifically target CLDN6 or do not bind to at least one member of its family, which requires massive screening. Specifically, the present invention screened at least 14,400 clones in total, and after three rounds of screening, including mother clone supernatant screening, subclone screening, and chimeric antibody screening, the chimeric antibodies of CLDN6 satisfying the properties of CLDN6 binding, tumor cell binding, ADCC properties, CDC properties, endocytosis, etc. as described in the present invention were finally obtained, as well as the humanized antibodies modified / improved and / or screened on this basis. 2.5 Humanized Antibodies In order to reduce the immunogenicity of the antibody to humans, the sequence of the anti-CLDN6 antibody of the present disclosure obtained by screening is used to produce a humanized anti-CLDN6 antibody, and the CDR region of the anti-CLDN6 antibody of mouse origin is combined with the framework region of human origin (e.g., human immunoglobulin) to form the humanized anti-CLDN6 antibody of the present disclosure. This humanized antibody retains the function of binding to human CLDN6 and the function of binding to monkey CLDN6. To prepare humanized antibodies, the mouse CDR regions can be inserted into human framework sequences using methods known in the art (see U.S. Pat. No. 5,225,539 to Winter; U.S. Pat. Nos. 5,530,101 to Queen et al.; 5,585,089; 5,693,762; and Lo, Benny, KC, editor in Antibody Engineering: Methods and Protocols, volume 248, Human Press, New Jersey, 2004). In the present invention, the full-length sequence of the humanized antibody can be obtained by connecting the variable region sequence of the humanized antibody in Table B with the IgG1 constant region in Table E, for example, the heavy chain variable region of the humanized antibody in Table B and the IgG1 heavy chain constant region in Table E, and the light chain variable region of the humanized antibody in Table B and the IgG1 light chain constant region in Table E, respectively. Optionally, the signal peptide sequence shown in Table E can also be connected to the variable region. 2.6 Antibody Improvement The method for improving the antibody includes recombination and conservative amino acid substitution to obtain an improved antibody with excellent / satisfactory CLDN6 binding properties and tumor therapeutic / inhibitory properties. Specifically, as an example, the present invention combines the heavy chain of 51C10H4 with the light chain of 54B5A7 to produce a new and improved chimeric monoclonal antibody RecA101. Specifically, as an example, the present invention mutates the deamidation hotspot NG of CDR2 of 20A3-2A7, and mutates the G in NG to A to obtain the improved antibody 20A3-M1 (composed of the heavy chain shown in the sequence of SEQ ID NO: 161 and the light chain shown in the sequence of SEQ ID NO: 173). It should be understood that other mutations can also be performed on this site NG. You can also mutate the G in NG to S / D / Q, and mutate the N in NG to S / Q / A to obtain other improved antibodies. Specifically, as an example, the present invention mutates the deamidation hotspot NG of CDR2 of 20A3-2A7, and mutates G in NG to Q to obtain the improved antibody 20A3-M2 (composed of the heavy chain shown in the sequence of SEQ ID NO: 162 and the light chain shown in the sequence of SEQ ID NO: 173). It should be understood that this site NG can also be mutated in other ways, and G in NG can also be mutated to S / D / A, and N in NG can be mutated to S / Q / A to obtain other improved antibodies. Specifically, as an example, the present invention mutates the deamidation hotspot NG of CDR2 of 51C10H4, and mutates G in NG to A to obtain the improved antibody 51C10-M1 (composed of the heavy chain shown in the sequence of SEQ ID NO: 163 and the light chain shown in the sequence of SEQ ID NO: 88). It should be understood that this site NG can also be mutated in other ways, and G in NG can also be mutated to S / D / Q, and N in NG can be mutated to S / Q / A to obtain other improved antibodies. Specifically, as an example, the present invention mutates the deamidation hotspot NG of CDR2 of 51C10H4, and mutates N in NG to Q, thereby obtaining the improved antibody 51C10-M2 (composed of the heavy chain shown in the sequence of SEQ ID NO: 164 and the light chain shown in the sequence of SEQ ID NO: 88). Specifically, as an example, the present invention mutates the isomerization site DG of the CDR3 region of 51C10H4, and mutates the G in DG to A to obtain the improved antibody 51C10-M3 (composed of the heavy chain shown in the sequence of SEQ ID NO: 165 and the light chain shown in the sequence of SEQ ID NO: 88). It should be understood that other mutations can also be performed at this site DG, and the D in DG can also be mutated to E / S / G, or the G can be mutated to A / S / D / Q to obtain other improved antibodies. Specifically, as an example, the present invention mutates the isomerization site DG of the CDR3 region of 51C10H4, mutates the D in DG to E, and obtains the improved antibody 51C10-M4 (composed of the heavy chain shown by the sequence of SEQ ID NO:166 and the light chain shown by the sequence of SEQ ID NO:88). It should be understood that in this way, in the antibodies of the present invention containing the deamidation hotspot NG, such as the CDR2 of 15H2D4, the CDR2 of 54B5A7, and the CDR2 of RecA101, the same or similar mutations can be performed, for example, mutating G in NG to A / S / D / Q or mutating N to S / Q / A, to obtain corresponding improved antibodies. It should be understood that in this way, in the antibodies of the present invention containing the isomerization site DG, such as CDR2 of 58G3C7, CDR3 of 54B5A7, CDR3 of RecA101, CDR3 of 51C10-M1, and CDR3 of 51C10-M2, the same or similar mutations can be made, mutating G in DG to A / S / D / Q or mutating D to E / S / G to obtain corresponding improved antibodies. It should be understood that the above two sites, such as the deamidation hotspot NG and the isomerization site DG, can be mutated at the same time, and other hotspot regions disclosed in the prior art for improving antibody properties can also be mutated in the antibodies of the present invention. It should be understood that the site mutations for improving antibodies in the present invention can not only be improved by site mutations based on chimeric antibodies as shown above, but also, in the same or similar manner, site mutations can be performed in the CDR region of humanized antibodies to obtain improved antibodies corresponding to humanized antibodies. Specifically, as an example, the present invention mutates the deamidation hotspot NG of CDR2 of the heavy chain of PiH1004, and mutates the G in NG to A, thereby obtaining the improved antibody PiH1004-M1 (composed of the heavy chain shown in the sequence of SEQ ID NO:167 and the light chain shown in the sequence of SEQ ID NO:174). Specifically, as an example, the present invention mutates the V of the CDR2 of the heavy chain of PiH1004 to A / I / L, and obtains the corresponding improved antibody (composed of the heavy chain variable region shown in the sequence of SEQ ID NO: 105 and the light chain variable region shown in the sequence of SEQ ID NO: 69, the heavy chain variable region shown in the sequence of SEQ ID NO: 106 and the light chain variable region shown in the sequence of SEQ ID NO: 107). The variable region of the light chain is composed of the sequence of SEQ ID NO: 69, the variable region of the heavy chain is composed of the sequence of SEQ ID NO: 107, and the variable region of the light chain is composed of the sequence of SEQ ID NO: 69. Specifically, as an example, the present invention mutates T of CDR2 of the heavy chain of PiH1004, mutating T to S, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:108 sequence and the light chain variable region shown in the SEQ ID NO:69 sequence). Specifically, as an example, the present invention mutates L of CDR3 of the heavy chain of PiH1004, mutating L to V, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in SEQ ID NO: 109 and the light chain variable region shown in SEQ ID NO: 69). Specifically, as an example, the present invention mutates Y of CDR3 of the heavy chain of PiH1004, mutating Y to F, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO: 110 sequence and the light chain variable region shown in the SEQ ID NO: 69 sequence). Specifically, as an example, the present invention mutates V of CDR3 of the heavy chain of PiH1004, mutating V to S, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown by SEQ ID NO:111 and the light chain variable region shown by SEQ ID NO:69). Specifically, as an example, the present invention mutates D of CDR1 of the light chain of PiH1004, mutating D to E, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:112 sequence). Specifically, as an example, the present invention mutates I of CDR1 of the light chain of PiH1004, mutating I to V, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:113 sequence). Specifically, as an example, the present invention mutates N of CDR1 of the light chain of PiH1004, mutating N to Q, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:114 sequence). Specifically, as an example, the present invention mutates A of CDR2 of the light chain of PiH1004, mutating A to G, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:115 sequence). Specifically, as an example, the present invention mutates T of CDR3 of the light chain of PiH1004, mutating T to S, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:116 sequence). Specifically, as an example, the present invention mutates W of CDR3 of the light chain of PiH1004, mutating W to a hydrophobic aliphatic amino acid G, to obtain a corresponding improved antibody (composed of a heavy chain variable region shown in SEQ ID NO:52 and a light chain variable region shown in SEQ ID NO:117). Specifically, as an example, the present invention mutates S of CDR3 of the light chain of PiH1004, mutating the uncharged polar amino acid S into the positively charged polar amino acid G, to obtain the corresponding improved antibody (composed of the heavy chain variable region shown in the SEQ ID NO:52 sequence and the light chain variable region shown in the SEQ ID NO:118 sequence). Specifically, as an example, the present invention also includes the following improved CDR sequences in Table 1, and those skilled in the art can Different CDR sequences can be selected and combined according to actual needs to form a specific antibody. Table I. Heavy chain CDR sequences of improved antibodies Table J Improved antibody light chain CDR sequences Table K. CDR amino acid sequences of improved antibodies It should be understood that with respect to the CDR regions of the mutant antibodies shown in Table K, those skilled in the art can not only improve the PiH1004 antibody, but can also make the same or similar improvements to other sequences in the present application, such as 51C10H4, 54B5A7, RecA101, PiH1001-PiH1008, PiH2001-PiH2012, etc. It should be understood that when other antibodies in the present invention contain the above-mentioned sites, the above-mentioned mutation method can also be performed in other antibodies in the present invention. Experiments have confirmed that the improved antibodies of the present invention do not substantially change the ability of the antibodies to bind to cells expressing CLDN6, and exhibit binding properties to a variety of tumor cells. 2.7 Antibody Purification Expi293F cells containing the antibody sequence plasmid were cultured in a shake flask and purified with ProteinA Magnetic Beads (GenScript Biotech, L00695). Elution was performed using 0.1M citric acid and sodium citrate buffer at pH 3.0. Neutralization was performed using Tris.HCl buffer at pH 9.0. After dialysis in PBS at pH 7.4, the concentration and purity of the antibody were determined using Nanodrop 2000 (Thermo) with an extinction coefficient of 1.43. The antibody concentration could reach 3 mg / mL. The antibody concentration (0.5 mg / ml-3 mg / ml) was verified by denaturing and non-denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion high performance liquid chromatography (SEC-HPLC). Example 3. Determination of the binding ability of antibodies to CLDN6 To detect the binding ability of chimeric antibodies or humanized antibodies to CLDN6, the cell line HEK293T-CLDN6 expressing CLDN6 and the negative control cell line HEK293T not expressing CLDN6 were washed three times with PBS. 1×10 5 The cells were incubated at 4°C for 1 hour with 50 μL of the test antibody solution. The cells were then washed 3 times with PBS, and the chimeric or humanized antibodies bound to CLDN6 were combined with Alexa 647-labeled anti-human IgG antibodies and incubated at 4°C for 45 minutes. Finally, the cells were washed 3 times with PBS, and the signals were read by FACS. The results are shown in Table 1. Table 1. FACS results of chimeric antibodies on HEK293T and HEK293T-CLDN6 Figures 1, 2, 3, 4 and 5 are respectively the binding capacity diagrams of chimeric antibodies, improved chimeric monoclonal antibody RecA101 and humanized antibodies on HEK293T-CLDN6, and the concentration of the antibody is plotted against the FACS signal (Geometric mean). The EC50 value (the antibody concentration that binds to half of the binding sites at equilibrium) was calculated by nonlinear regression, and the corresponding EC50 values are shown in Tables 2, 3, 4, 5 and 6. Table 2. EC50 values of some chimeric antibodies on HEK293T-CLDN6 (unit: μg / mL) Table 3. EC50 values of some chimeric antibodies on HEK293T-CLDN6 (unit: μg / mL) Table 4. EC50 values of improved chimeric mAbs on HEK293T-CLDN6 (unit: μg / mL) Table 5. EC50 values of humanized antibodies (PiH1001-PiH1008) on HEK293T-CLDN6 (unit: μg / mL) Table 6. EC50 values of humanized antibodies (PiH2001-PiH2008) on HEK293T-CLDN6 From the above results, it can be seen that compared with the chimeric antibody 54B5A7 that has not been humanized, the binding activity of the humanized antibody has not been substantially reduced. Moreover, the chimeric antibodies, improved chimeric monoclonal antibodies and humanized antibodies screened by the present invention all have excellent CLDN6 binding properties, and the binding properties of some chimeric antibodies are significantly better than those of the benchmark antibody IMAB027, especially under high concentration conditions. And the inventors further found through experiments that compared with the chimeric antibody 54B5A7 that has not been humanized, PiH2012 has comparable binding activity to CLDN6 (not shown in the figure). Example 4. Determination of the binding ability of chimeric antibodies and improved antibody RecA101 to CLDN3 / 4 / 9 Flow cytometry (FACS) was used to detect the specific binding of chimeric antibodies and improved antibodies RecA101, 20A3-M1, 20A3-M2, 51C10-M1, and the PiH1004 improved antibody in Table G (Table H) to cells expressing CLDN6, as well as to cells expressing CLDN3, CLDN4 and CLDN9. Add 50 μL of the antibody to be tested into a 96-well plate and add 1×10 5 cells, incubated at 4°C for 1 hour. The cells were washed 3 times with PBS, and the chimeric antibody or humanized antibody bound to CLDN6 was bound using Alexa 647 labeled anti-human IgG antibody, and incubated at 4°C for 45 minutes. Finally, the cells were washed 3 times with PBS, and the signals were read by FACS. The binding ability to CLDN9 / CLDN3 / CLDN4 was analyzed according to the detection information, and the results are shown in Figures 6 to 12. Meanwhile, Tables 7 to 9 show the FACS detection ratio results of partial chimeric antibodies and improved antibodies on 293T-CLDN6, 293T-CLDN3 / 4 / 9, and Table 7 shows the FACS detection ratio results of partial chimeric antibodies on 293T-CLDN6 / 293T-CLDN9. Table 7. FACS detection results of some chimeric antibodies on 293T-CLDN6 / 293T-CLDN3 / 4 / 9 Table 8. FACS detection results of improved antibodies on 293T-CLDN6 / 293T-CLDN3 / 4 / 9 (10 μg / ml) Table 9. FACS detection results of improved antibodies on 293T-CLDN6 / 293T-CLDN3 / 4 / 9 (10 μg / ml) It can be seen from the above results that the chimeric antibodies of the present invention have obvious CLDN6 binding specificity, and are significantly better than the binding specificity of the benchmark antibody IMAB027. Although some antibodies have binding signals on CLDN3, CLDN4, or CLDN9, their binding signals are significantly lower than the binding signals on CLDN6, and the difference is even hundreds of times. For example, for antibodies with certain CLDN9 binding, the CLDN6 / CLDN9 signal ratio of some antibodies reaches about 200 times, for example, 54B5A7, 51C10H4; although some antibodies have detectable CLDN9 binding, their CLDN6 / CLDN9 signal ratio also reaches about 50 times, for example, 58G3C7, 47D5D6, 20A3-2A7. The improved antibodies of the present invention, including 20A3-M1, 20A3-M2, 51C10-M1 and RecA101, also have significant CLDN6 binding specificity. Compared with the control antibody IMAB027, 20A3-M1 and 20A3-M2 in particular show significantly weaker CLDN9 binding. As shown in Figure 13, the results of chimeric antibodies 51C10H4 and 54B5A7 at a concentration of 5 μg / mL with cell lines HEK293T-CLDN6, HEK293T-CLDN9, HEK293T-CLDN3, and HEK293T-CLDN4. The results show that the chimeric antibodies 51C10H4 and 54B5A7 have better specificity for HEK293T-CLDN9 than IMAB027. In addition, these two chimeric antibodies have almost no binding to CLDN3 and CLDN4, and their binding to CLDN9 is hundreds of times weaker than that to CLDN6, thereby maximizing the therapeutic effect and minimizing systemic toxicity. The inventors further found that the binding abilities of humanized antibodies PiH1001-PiH1008 to CLDN3 / 4 / 9 were comparable to those of the non-humanized 51C10H4, and the binding abilities of humanized antibodies PiH2001, PiH2004, PiH2005, PiH2006, PiH2007, PiH2008, PiH2009, PiH2010, PiH2011, and PiH2012 to CLDN3 / 4 / 9 were comparable to those of the non-humanized 54B5A7. Figure 42 shows the binding ability of PiH1004 improved antibodies in Table G (Table H), such as PiH1004-VH-Mutation1-VL, PiH1004-VH-Mutation8-VL, PiH1004-VH-VL-Mutation1, etc., to CLDN6. It can be seen that compared with the antibody PiH1004, these site-directed mutations of the improved antibodies do not reduce their binding ability to CLDN6, and in some site-directed mutations, the binding ability of the improved antibodies to CLDN6 is improved. In addition, the present disclosure also tested the binding ability of the antibodies in Table K to CLDN6. Compared with the unmutated antibody (PiH1004), the mutations of these improved antibodies also did not reduce their binding ability to CLDN6 (not shown in the figure). Example 5. Determination of mouse and monkey cross-reactivity of antibodies As described above, flow cytometry (FACS) was used to detect the binding of chimeric or humanized antibodies to overexpressed mouse CLDN6. cells and cells expressing monkey CLDN6. Figures 14, 15, 16 and 17 show the binding results of chimeric antibodies to cells overexpressing mouse and monkey CLDN6, respectively. Figures 18, 19, 20 and 21 show the binding results of humanized antibodies to cells overexpressing mouse and monkey CLDN6, respectively. The corresponding EC50 values are shown in Table 10. Table 10. EC50 values of chimeric antibodies binding to cells overexpressing mouse and monkey CLDN6 (unit: μg / mL) It can be seen from the results in Table 10 and Figures 14 to 17 that the chimeric antibodies of the present invention have good binding ability to cells overexpressing mouse and monkey CLDN6. From the results of Figures 18 to 21, it can be seen that compared with the non-humanized antibodies, the humanized antibodies of the present invention have significantly reduced ability to bind to mouse CLDN6 cells overexpressing the CLDN6, especially the humanized antibodies of the 54B5A7 antibody hardly bind to mouse CLDN6 cells overexpressing the CLDN6, which indicates that the humanization modification of the present invention successfully reduces / avoids cross-reactivity between species. Example 6. Determination of the binding ability of antibodies to tumor cells and the inhibitory effect Flow cytometry (FACS) was used to detect the specific binding of the chimeric antibody to tumor cells, and the EC50 value was calculated to evaluate the inhibitory effect of the antibody on tumor cells. Add 50 μL of the antibody to be tested into a 96-well plate and add 1×10 5cells, incubated at 4°C for 1 hour. The cells were washed with PBS 3 times, and the anti-human IgG antibody labeled with Alexa 647 was used to bind to the antibody to be tested that was bound to the corresponding tumor cells, and incubated at 4°C for 45 minutes. Finally, the cells were washed with PBS 3 times, and the signals were read by FACS. The binding ability of the antibody to be tested to various tumor cells was analyzed according to the detection information, and the results are shown in Figures 22 to 36. Among them, Figures 22 to 27 are the binding ability diagrams of chimeric antibodies, improved chimeric monoclonal antibodies Rec101A, and humanized antibodies against HepG2. Figures 28 to 31 are the binding ability diagrams of chimeric antibodies and humanized antibodies against PA-1. Figures 32 to 36 are the binding ability diagrams of the improved antibody 20A3-M1 to various tumor cells, including human lung adenocarcinoma cells H1975, human colon adenocarcinoma cells LS174T, human ovarian cancer cells OVCAR3, human prostate cancer cells PC-3, and human pancreatic cancer cells Capan-2. Figure 43 is a graph showing the binding ability of PiH1004 and PiH2012 to ovarian cancer cells OVCA429. Figure 44 is a graph showing the binding ability of PiH1004 and PiH2012 to highly expressed human gastric cancer cells MKN7. Meanwhile, Tables 11 to 15 also show the EC50 values of these antibodies on tumor cells calculated according to Figures 22 to 36. Table 16 shows the FACS detection results of the improved antibodies against HepG2 at a concentration of 5 μg / ml. Table 11. EC50 values of partially chimeric antibodies against tumor cells Table 12. EC50 values of some chimeric antibodies against tumor cells Table 13. EC50 values of humanized antibodies Table 14. EC50 values of humanized antibodies Table 15. EC50 values of humanized antibodies Table 16. FACS detection results of improved antibodies (antibody concentration: 5 μg / ml) As can be seen from the above results, firstly, the chimeric antibodies and humanized antibodies of the present invention significantly bind to tumor cells PA-1 and HepG2 with very low EC50 values, and have significant inhibitory / killing activity against tumor cells in vitro. The inhibitory / killing activity of some chimeric antibodies is comparable to or better than that of the benchmark antibody IMAB027. IMAB027 indicates the therapeutic prospect of the antibody of the present invention for ovarian cancer and liver cancer. In addition, it can be seen from Table 16 that the binding effect on tumor cells HepG2 is comparable to that before the improvement, indicating that the improvement / mutation of the present invention does not reduce the tumor inhibition activity. Various antibodies in the present invention also show good effects in other tumor cells. It has been verified that, as shown in Figure 24, the recombined chimeric monoclonal antibody Rec101A shows a binding ability that is better than the positive antibody on HepG2 cells. As shown in Figures 32 to 38, the improved antibody 20A3-M1 in the present invention also shows binding activity with a variety of tumor cells, such as human lung adenocarcinoma cell H1975, human colon adenocarcinoma cell LS174T, human ovarian cancer cell OVCAR3, human prostate cancer cell PC-3, pancreatic cancer cell Capan-2, human ovarian teratoma cell PA-1, and liver cancer cell HepG2 all show significant binding properties. Similar effects were also observed for other improved antibodies 51C10-M1, 51C10-M2, 51C10-M3, and 51C10-M4. As shown in Figure 43, PiH1004 and PiH2012 showed stronger binding ability with ovarian cancer cell OVCA429 than the positive control AB3-7. As shown in the figure, PiH1004 and PiH2012 showed stronger binding ability with the highly expressed human gastric cancer cell MKN7 than the positive control AB3-7. Furthermore, public literature has found that CLDN6 is highly expressed in various cancer tissues and corresponding tumor cells such as ovarian cancer, lung cancer, gastric cancer, breast cancer, liver cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, renal cell carcinoma, and uterine cancer. Therefore, the chimeric antibodies, humanized antibodies, and improved antibodies of the present invention can also be expected to have these tumor treatment effects. Example 7. Antibody-dependent cellular cytotoxicity (ADCC) method Collect the effector cells (NK92 / CD16A-VV) and resuspend them in ADCC assay buffer (99% MEMα, nucleosides, phenol red-free + 1% fetal bovine serum). Collect the target cells (CHO-K1-CLDN6) and resuspend them in ADCC assay buffer. Prepare the test and control working solutions with ADCC assay buffer. Adjust the target cell density with ADCC assay buffer and transfer the target cell suspension to a 96-well assay plate. Transfer the test, control working solution or ADCC assay buffer to the corresponding wells of the 96-well assay plate. Incubate the assay plate at room temperature for 30 minutes. Adjust the effector cell density with ADCC assay buffer according to the E / T ratio and transfer the effector cell suspension to the corresponding wells of the 96-well assay plate. Incubate the assay plate in a cell culture incubator (37°C / 5% CO2) for 6 hours. After the incubation is completed, remove the 96-well assay plate, centrifuge and carefully aspirate the incubation supernatant and transfer it to a new 96-well assay plate. Transfer the LDH detection working solution (lactose dehydrogenase detection working solution) to the corresponding wells of a new 96-well experimental plate and develop the color at room temperature. Read the OD value on the microplate reader, the detection wavelength is 492nm, and the reference wavelength is 650nm. The effector cells used in this experiment are: NK92 / CD16A-VV, target cells CHO-K1-CLDN6, under the condition of 3:1 effector cells and target cells, the test samples (54B5A7 and 51C10H4) and human IgG1 were gradiently diluted, incubated with the corresponding target cells for 6 hours, and the target cell lysis percentage was detected. The results are shown in Figure 39 and Table 17. The data in the figure are expressed as the target cell lysis percentage Mean±SEM. Table 17. ADCC dose response experiment fitting parameters It can be seen from Table 17 and Figure 39 that under the current experimental conditions, the chimeric antibodies 54B5A7 and 51C10H4 CHO-K1-CLDN6 cells showed obvious ADCC effect and could effectively induce cells to kill tumor cells expressing CLDN6, while the negative control (human IgG1) did not show ADCC effect on CHO-K1-Claudin6 cells. Example 8. Complement Dependent Cytotoxicity (CDC) Method The target cells (CHO-K1-CLDN6) were cultured in complete medium in a cell culture incubator at 37°C / 5% CO2, the effector molecule was 5% NHSC (normal human serum complement), the highest concentration was 50 μg / mL, the dilution factor was 5 times, and 8 concentration points were taken. Collect target cells and resuspend them with CDC assay buffer, prepare test and control substances with CDC assay buffer, adjust target cell density and transfer cell suspension to 384-well assay plate, transfer control substance / test substance working solution to corresponding wells of 384-well assay plate, and incubate the assay plate at room temperature for 30 minutes, prepare NHSC working solution and transfer to corresponding wells of 384-well assay plate, incubate the assay plate in a cell culture incubator (37°C / 5% CO2) for 4 hours, remove the assay plate after incubation, add Cell (Promega, catalog number G7573) working solution, incubate at room temperature for 10 minutes, and read the chemiluminescence value using an enzyme reader. The raw data of the CDC experiment were exported via the PHERA Star FSX system and analyzed using Microsoft Office Excel 2016 and GraphPad Prism 6 software. Under 5% NHSC conditions, the positive reference, test sample and human IgG1 were gradiently diluted and incubated with the corresponding target cells (CHO-K1-CLDN6) for 4 hours to detect the percentage of target cell lysis. The results are shown in Figure 40 and Table 18. The data in the figure are expressed as the mean ± SEM of the percentage of target cell lysis. Table 18. CDC dose response experiment fitting parameters As can be seen from Figure 40 and Table 18, chimeric antibodies 54B5A7 and 51C10H4 can effectively mediate the CDC effect on CHO-K1-CLDN6 cells, while the negative control (human IgG1) cannot mediate the CDC effect on CHO-K1-CLDN6 cells. Example 9. Aggregation stability Enter the sample information and location according to the operating instructions of Uncle high-throughput multi-parameter protein stability analyzer. Dilute the sample to the same concentration and centrifuge at 12000rmp for 3 minutes. Add 9μL of sample to the corresponding UNi tube and seal the two ends of the UNi tube with silicone. Set the heating parameter range from 25℃ to 95℃, the heating rate is 0.5℃ / min, load the sample and run the program. Use Uncle analysis software to calculate Tm and Tagg. The results are shown in Table 19. Table 19. Tm and Tagg results of antibodies From the results in Table 19, it can be seen that the chimeric antibodies 54B5A7 and 51C10H4 of the present invention have better aggregation stability than the benchmark antibody IMAB027, which indicates that their binding window to cells expressing CLDN6 will be higher. Example 10. Endocytosis test The present disclosure uses DT3C recombinant protein (Huamei Bio, catalog number: CSB-EP360556CQR1) to measure the internalization and immunotoxin activity of antibodies. The DT3C is a protein formed by genetically fusing the catalytic region of diphtheria toxin (DT) and the antibody binding region of streptococcal protein G. DT3C specifically binds to the Fc portion of the antibody, and if engulfed into the cell, it induces cell death by inhibiting protein synthesis. By using this system, the internalization of the antibody and the cell killing effect caused by the immunotoxin can be observed simultaneously. PA-1 cells were cultured, and cells in logarithmic growth phase were inoculated with 40 μL in a 384-well plate at a density of 500 cells / well, and cultured overnight at 37°C, 5% CO2. Chimeric antibodies, reference antibodies, and negative control human IgG1 were mixed with DT3C protein at a ratio of 1:2, and incubated at room temperature for 30 minutes to form mAb-DT3C conjugates. The conjugates were added to 384-well plates and cultured at 37°C, 5% CO2 for 3 days. 20 μL of CellTiter-Glo assay kit (CTG) reagent (Promega, catalog number: G7573) was added to each well and left at room temperature for 30 minutes. The luminescence value was recorded using an Envision 2105 microplate reader. The results are shown in FIG41 . As can be seen from Figure 41, the inhibition rate of the DT3C conjugate of 54B5A7, 20A3-2A7 and 51C10H4 on PA-1 cells reached more than 90% at a concentration of 4.2 nM, which is comparable to the benchmark antibody IMAB027, indicating that the chimeric antibodies 54B5A7, 20A3-2A7 and 51C10H4 have significant internalization effects on PA-1 cells. Example 11. Therapeutic effect of anti-CLDN6 antibody in RRV-induced mouse BA model The test CLDN6 antibody used in this example is an antibody whose variable region is derived from 54B5A7 and whose constant region adopts the constant region of mouse IgG2a. Dosing conditions: RRV was injected intraperitoneally within 24 hours after birth of the suckling mice, and anti-CLDN6 antibody solution was injected intraperitoneally 4 to 6 hours later. The drug was administered starting on day 0 and every two days, with a single dose of 1 mg / kg for a total of 4 times. The weight of the suckling mice was recorded every day, and the jaundice phenotype of the suckling mice was observed. On the 12th day after birth, the liver tissue of the mice was obtained, paraffin-embedded, and the liver pathology was observed by HE and Masson staining; the liver tissue RNA was extracted by Trizol method, and the changes in the mRNA levels of related genes were analyzed by real-time fluorescence quantitative analysis. The results are shown in Figures 45 to 57. During the RRV-induced mouse BA model, the mRNA levels of liver fibrosis-related genes and tight junction protein-related genes were upregulated (Figures 47 to 56). After administration of anti-CLDN6 antibodies, the weight of mice increased and improved, approaching that of the control group (Figure 45). The jaundice rate decreased (Figure 46). The levels of liver fibrosis-related gene mRNA and tight junction protein-related gene mRNA were reduced (Figures 47 to 56). The expression of tight junction proteins was improved, which had the effect of delaying liver damage and improving the level of liver fibrosis (Figure 57). Incorporated by Reference Each patent document and scientific document mentioned herein is incorporated by reference in its entirety for all purposes. Equivalence The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The formula should be regarded in all cases as illustrative rather than restrictive of the invention described herein. The scope of the invention is therefore indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims
1. An isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The antibody comprises: (1) CDRH1, which comprises or consists of the sequence X1YNMH, wherein X1 is selected from D or S; (2) CDRH2 comprising or consisting of the sequence YX1X2PX3X4X5X6TX7YNQKFKG, X1 is selected from V or I, X2 is selected from N or Y, X3 is selected from N or G, X4 is selected from N or Q or S or A, X5 is selected from A or G or D or Q or S, X6 is selected from A or G, and X7 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WX1X2YVYYYGX3DY or SEQ ID NO: 23, X1 is selected from D or E or S or G, X2 is selected from A or G or S or D or Q, and X3 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27 or SEQ ID NO: 29; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 30 or SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT or SEQ ID NO: 40, X 1 is selected from S or N; Preferably, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNX2X3ATX4YNQKFKG, wherein X1 is selected from V or I, X2 is selected from N or Q or S or A, X3 is selected from A or G or D or Q or S, and X4 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N; Further preferably, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of the sequence YX1NPNNGATX2YNQKFKG, wherein X1 is selected from V or I, and X2 is selected from S or N; (3) CDRH3 comprising or consisting of the sequence WDGYVYYYGX1DY, wherein X1 is selected from L or M; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of the sequence SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of the sequence QQYWX1TPYT, wherein X1 is selected from S or N; Or the antibody comprises: (1) CDRH1, which comprises or consists of the sequence SYX1IX2, wherein X1 is selected from N or G, and X2 is selected from H or S; (2) CDRH2 comprising or consisting of the sequence X1IYPX2X3GX4TX5X6NEX7FKG, wherein X1 is selected from Y or E, X2 is selected from G or R, X3 is selected from N or S, X4 is selected from G or N, X5 is selected from K or Y, X6 is selected from Y or H, and X7 is selected from R or K; (3) CDRH3 comprising the sequence SEQ ID NO: 16 or SEQ ID NO: 17 ID NO: 19; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 24 or SEQ ID NO: 26; (5) CDRL2 comprising or consisting of the sequence X1X2SNLX3S, wherein X1 is selected from L or G, X2 is selected from A or T, and X3 is selected from E or A; and (6) CDRL3 comprising or consisting of the sequence SEQ ID NO: 34 or SEQ ID NO: 179; Or the antibody comprises: (1) CDRH1 comprising or consisting of the sequence X1YX2MS, wherein X1 is selected from S or N, and X2 is selected from G or A; (2) CDRH2 comprising or consisting of the sequence TISX1GGSYTX2YPDX3X4KG, wherein X1 is selected from S or D, X2 is selected from Y or S, X3 is selected from S or N, and X4 is selected from V or I; (3) CDRH3 comprising or consisting of the sequence SEQ ID NO: 17 or SEQ ID NO: 18; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 25; (5) CDRL2 comprising or consisting of the sequence X1X2TSLET, wherein X1 is selected from G or A, and X2 is selected from A or T; and (6) CDRL3, which comprises or consists of the sequence QQYWS X1PX2T, wherein X1 is selected from T or F, and X2 is selected from P or R.
2. An isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the isolated antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The heavy chain variable region comprises: (i) a CDRH1 comprising any one of the sequences shown in SEQ ID NOs: 1-5 and 7 or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NOs: 1-5 and 7; (ii) a CDRH2 comprising any one of the sequences set forth in SEQ ID NOS: 8-13, 15, and 74-76, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOS: 8-13, 15, and 74-76; and (iii) a CDRH3 comprising any one of the sequences set forth in SEQ ID NOs: 16-21, 23, and 77-78, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 16-21, 23, and 77-78; The light chain variable region comprises: (i) CDRL1 comprising any one of the sequences shown in SEQ ID NOs: 24-27 and 29 or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NOs: 24-27 and 29; (ii) CDRL2, which comprises any one of the sequences shown in SEQ ID NOs: 30-33, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NOs: 30-33; and (iii) CDRL3, which comprises any one of the sequences shown in SEQ ID NOs: 34-38, 40 and 179, or any one of the sequences having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NOs: 34-38, 40 and 179.
3. The antibody or antigen-binding portion thereof of claim 1 or 2, wherein the isolated antibody or antigen-binding portion thereof comprises: (a) comprising a CDRH1 shown in any one of SEQ ID NOs: 1-5 and 7; (b) comprising a CDRH2 shown in any one of SEQ ID NOs: 8-13, 15, 74-76; (c) comprising a CDRH3 shown in any one of SEQ ID NOs: 16-21, 23, 77-78; (d) comprising CDRL1 shown in any one of SEQ ID NOs: 24-27 and 29; (e) comprising CDRL2 shown in any one of SEQ ID NOs: 30-33; and (f) comprising CDRL3 shown in any one of SEQ ID NOs: 34-38, 40 and 179.
4. The antibody or antigen-binding portion thereof according to claim 1 or 2, wherein the isolated antibody or antigen-binding portion thereof comprises: (a) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 1; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 8; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 16; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 24; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 30; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 34; (b) comprising CDRH1 as set forth in or consisting of SEQ ID NO: 2; comprising CDRH2 as set forth in or consisting of SEQ ID NO: 9; comprising CDRH3 as set forth in or consisting of SEQ ID NO: 17; comprising CDRL1 as set forth in or consisting of SEQ ID NO: 25; comprising CDRL2 as set forth in or consisting of SEQ ID NO: 31; and comprising CDRL3 as set forth in or consisting of SEQ ID NO: 35; (c) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 3; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 10; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 18; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 25; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 32; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 36; (d) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 4; a CDRH2 as set forth in or consisting of SEQ ID NO: 11; a CDRH3 as set forth in or consisting of SEQ ID NO: 19; a CDRL1 as set forth in or consisting of SEQ ID NO: 26; a CDRL2 as set forth in or consisting of SEQ ID NO: 33; and a CDRL3 as set forth in or consisting of SEQ ID NO: 179; (e) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 5; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 12; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 20; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 27; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 31; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 37; (f) comprising CDRH1 as shown in or consisting of SEQ ID NO: 5; comprising CDRH2 as shown in or consisting of SEQ ID NO: 13; comprising CDRH3 as shown in or consisting of SEQ ID NO: 21; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO: 38; or (g) comprising CDRH1 as shown in SEQ ID NO: 7 or consisting thereof; comprising CDRH2 as shown in SEQ ID NO: 15 or consisting thereof; comprising CDRH3 as shown in SEQ ID NO: 23 or consisting thereof; comprising CDRL1 as shown in SEQ ID NO: 29 or consisting thereof; comprising CDRL2 as shown in SEQ ID NO: 30 or consisting thereof; and comprising CDRL3 as shown in SEQ ID NO: 40 or consisting thereof; or (h) CDRH1 comprising or consisting of SEQ ID NO: 5; or CDRH1 comprising or consisting of SEQ ID NO: 12 comprising or consisting of a CDRH2 as shown in or consisting of SEQ ID NO: 20; comprising or consisting of a CDRH3 as shown in or consisting of SEQ ID NO: 27; comprising or consisting of a CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising or consisting of a CDRL3 as shown in or consisting of SEQ ID NO: 38; or (i) comprising a CDRH1 as set forth in or consisting of SEQ ID NO: 7; comprising a CDRH2 as set forth in or consisting of SEQ ID NO: 24; comprising a CDRH3 as set forth in or consisting of SEQ ID NO: 23; comprising a CDRL1 as set forth in or consisting of SEQ ID NO: 29; comprising a CDRL2 as set forth in or consisting of SEQ ID NO: 30; and comprising a CDRL3 as set forth in or consisting of SEQ ID NO: 40; or (j) comprising CDRH1 as shown in or consisting of SEQ ID NO:5; comprising CDRH2 as shown in or consisting of SEQ ID NO:75; comprising CDRH3 as shown in or consisting of SEQ ID NO:20; comprising CDRL1 as shown in or consisting of SEQ ID NO:27; comprising CDRL2 as shown in or consisting of SEQ ID NO:31; and comprising CDRL3 as shown in or consisting of SEQ ID NO:37; or (k) comprising CDRH1 as set forth in or consisting of SEQ ID NO:5; comprising CDRH2 as set forth in or consisting of SEQ ID NO:76; comprising CDRH3 as set forth in or consisting of SEQ ID NO:20; comprising CDRL1 as set forth in or consisting of SEQ ID NO:27; comprising CDRL2 as set forth in or consisting of SEQ ID NO:31; and comprising CDRL3 as set forth in or consisting of SEQ ID NO:37; or (l) comprising CDRH1 as shown in or consisting of SEQ ID NO:5; comprising CDRH2 as shown in or consisting of SEQ ID NO:12; comprising CDRH3 as shown in or consisting of SEQ ID NO:77; comprising CDRL1 as shown in or consisting of SEQ ID NO:27; comprising CDRL2 as shown in or consisting of SEQ ID NO:31; and comprising CDRL3 as shown in or consisting of SEQ ID NO:37; or (m) comprising CDRH1 as shown in or consisting of SEQ ID NO: 5; comprising CDRH2 as shown in or consisting of SEQ ID NO: 12; comprising CDRH3 as shown in or consisting of SEQ ID NO: 78; comprising CDRL1 as shown in or consisting of SEQ ID NO: 27; comprising CDRL2 as shown in or consisting of SEQ ID NO: 31; and comprising CDRL3 as shown in or consisting of SEQ ID NO:
37.
5. The antibody or antigen binding portion thereof of any one of claims 1 to 4, wherein the heavy chain variable region comprises or consists of any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of SEQ ID NOs: 41-46, 48-60, 79-83, or any one of SEQ ID NOs: 85%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, and the light chain variable region comprises or consists of any one of SEQ ID NOs: 61-66, 68-73, or any one of SEQ ID NOs: 85%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity.
6. The antibody or antigen-binding portion thereof of any one of claims 1 to 5, wherein the isolated antibody or antigen-binding portion thereof comprises: (a) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 41 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 61; or (b) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 42 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 62; or (c) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 43 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 63; or (d) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 44 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 64; or (e) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 45 or 80-83 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 65; or (f) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 46 or 45 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 66; or (g) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 48 or 79 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 68; or (h) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 69; or (i) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 49-52 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 70; or (j) a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 53 or 54 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 71; or (k) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 53-56 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 72; or (l) a heavy chain variable region comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 57-60 and a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO:
73.
7. The antibody or antigen binding portion thereof of any one of claims 1 to 6, which has one or more of the following properties: (a) binds to human or monkey CLDN6 with an EC50 of 10 μg / mL or less; (b) the binding properties to human CLDN3, human CLDN4, and human CLDN9 are lower than the binding properties to human CLDN6, preferably the binding properties to human CLDN3 and human CLDN4 are lower than the binding properties to human CLDN6 and human CLDN9; (c) killing and / or inhibiting cells expressing human CLDN6.
8. An isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or the antigen-binding portion thereof competes with the antibody or the antigen-binding portion thereof according to any one of claims 1 to 7 for binding to CLDN6 expressed on the cell surface.
9. An isolated anti-CLDN6 antibody or an antigen-binding portion thereof, wherein the isolated antibody or the antigen-binding portion thereof comprises a complementary determining region sequence selected from the group consisting of SEQ ID NOs: 41-46, 48-60, 79-83 and a complementary determining region sequence selected from the group consisting of SEQ ID NOs: 61-66, 68-73.
10. An isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, The antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X 1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprises a sequence of SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125 or consisting thereof; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or It comprises or consists of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3, which comprises or consists of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27, or comprising or consisting of the sequence KASX1HX2NX3WLA, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1 comprising or consisting of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142; Preferably, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12, or comprising or consisting of the sequence YX1NPNNGAX2X3YNQKFKG, X1 is selected from A, I, L or V, X2 is selected from S or T, and X3 is selected from S or N; preferably, CDRH2 comprising or consisting of the sequence SEQ ID NO: 12, 91, 92, 93, 94, 119, 120, 121, 122, 123, 124, or 125; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20, or comprising or consisting of the sequence WDGYX1YYYGX2DX3, wherein X1 is selected from V or S, X2 is selected from V, L or M, and X3 is selected from Y or F; preferably, CDRH3 comprising or consisting of the sequence SEQ ID NO: 20, 95, 96, 97, 126, 127, 128, 129, 130, or 131; (4) CDRL1 comprising or consisting of the sequence SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of the sequence SEQ ID NO: 27, or which comprises the sequence KASX1HX2NX3WLA or consisting of the sequence, wherein X1 is selected from E or D, X2 is selected from I or V, and X3 is selected from H or Q; preferably, CDRL1, which comprises or consists of SEQ ID NO: 27, 98, 99, 100, 132, 133, 134, or 135; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2, which comprises or consists of SEQ ID NO: 31, or which comprises or consists of SEQ ID NO: 101; and (6) CDRL3, which comprises or consists of SEQ ID NO: 37; Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of SEQ ID NO: 12; (3) CDRH3 comprising or consisting of SEQ ID NO: 20; (4) CDRL1, which comprises or consists of SEQ ID NO: 27; (5) CDRL2 comprising or consisting of SEQ ID NO: 31; and (6) CDRL3 comprising or consisting of SEQ ID NO: 37, or comprising or consisting of QQYX1X2TPYX3, wherein X1 is selected from W or G, X2 is selected from S, H or N, and X3 is selected from S or T; preferably, CDRL3 comprising or consisting of SEQ ID NO: 37, 102, 103, 104, 136, 137, 138, 139, 140, 141, or 142. Alternatively, the antibody comprises: (1) CDRH1 comprising or consisting of SEQ ID NO: 5; (2) CDRH2 comprising or consisting of any one of SEQ ID NOs: 12, 91-94, 119-125; (3) CDRH3 comprising or consisting of any one of SEQ ID NOs: 20, 95-97, 126-131; (4) CDRL1, which comprises or consists of any one of SEQ ID NOs: 27, 98-99, 132-135; (5) CDRL2, which comprises or consists of SEQ ID NO: 31 or 101; (6) CDRL3, which comprises or consists of any one of SEQ ID NOs: 37, 102-104, 136-142; Preferably, the antibody comprises or consists of the CDRs shown in Table K.
11. An isolated anti-CLDN6 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises any one of SEQ ID NOs: 105-111, or a sequence consisting of thereof, or any one of SEQ ID NOs: 105-111 having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 105-111; the light chain variable region comprises SEQ ID NO: 69, or a sequence consisting of thereof, or any one of SEQ ID NOs: 69 having at least 85%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of SEQ ID NOs: 69; or wherein the heavy chain variable region comprises SEQ ID NO: 52 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 52; and the light chain variable region comprises SEQ ID NO: 112-118 or a sequence consisting of it, or any amino acid sequence or a sequence consisting of it having at least 80%, such as at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the sequence of SEQ ID NO: 112-118.
12. The antibody, or antigen binding portion thereof, of any one of claims 1 to 11, wherein the antibody is a monoclonal antibody.
13. The antibody, or antigen binding portion thereof, of any one of claims 1 to 11, wherein the antibody is a chimeric antibody or a humanized antibody.
14. The isolated antibody or antigen binding portion thereof of any one of claims 1 to 13, wherein the antibody comprises the constant region of IgG.
15. The isolated antibody or antigen binding portion thereof of claim 14, wherein the constant region of IgG is selected from an IgG1, IgG2, IgG3, or IgG4 constant region.
16. The isolated antibody or antigen binding portion thereof of claim 15, wherein the constant region of IgG is selected from the constant region of IgG1.
17. An antibody or antigen-binding portion thereof as described in any one of claims 1 to 16, which comprises or consists of a heavy chain selected from the group consisting of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 143-167 or SEQ ID NO: 87 or SEQ ID NO: 89; and a light chain comprising or consists of a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 168-178 or SEQ ID NO: 88 or SEQ ID NO:
90.
18. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the antibody or antigen binding portion thereof as described in any one of claims 1-17. A vector comprising the nucleic acid molecule according to claim 18 .
20. A host cell comprising the nucleic acid molecule of claim 18 or the vector of claim 19.
21. A conjugate comprising the antibody or antigen binding portion thereof according to any one of claims 1 to 17 coupled to at least one detectable label.
22. An antibody drug conjugate comprising an antibody, comprising one or more drug moieties, said drug moieties being linked (preferably covalently linked) directly or via a linker to the antibody or antigen binding portion thereof as claimed in any one of claims 1 to 17.
23. A multispecific molecule comprising the antibody or antigen binding portion of any one of claims 1-17; preferably, the multispecific molecule specifically binds to CLDN6 and additionally specifically binds to one or more other targets; further preferably, the multispecific molecule further comprises at least one molecule having a second binding specificity for a second target.
24. A chimeric antigen receptor (CAR) comprising an antibody or antigen binding portion thereof as described in any one of claims 1-17, and an immune cell activation portion, wherein the immune cell activation portion comprises a transmembrane domain of an immune cell receptor and / or an intracellular signal transduction domain of an immune cell receptor.
25. A pharmaceutical composition or kit comprising the antibody or antigen-binding portion thereof as described in any one of claims 1 to 17, or the nucleic acid molecule as described in claim 18, or the vector as described in claim 19, or the host cell as described in claim 20, or the conjugate as described in claim 21, or the antibody-drug conjugate as described in claim 22, or the multispecific molecule as described in claim 23, or the chimeric antigen receptor as described in claim 24; and a pharmaceutically acceptable carrier.
26. A method for preparing the antibody or antigen-binding portion thereof according to any one of claims 1 to 17, comprising the following steps: (i) expressing the antibody or antigen-binding portion thereof according to any one of claims 1 to 17 in a host cell according to claim 20; and optionally (ii) isolating the antibody or antigen-binding portion thereof from the host cell.
27. A method for detecting CLDN6 in a sample or determining the amount of CLDN6 in a sample, comprising the following steps: (i) contacting the sample with the antibody or antigen-binding portion of any one of claims 1 to 17 or the conjugate of claim 21, and (ii) detecting the formation of a complex between the antibody, antigen binding portion or conjugate and CLDN6, or determining the amount of the complex.
28. The method of claim 27, wherein the sample comprises cells.
29. Use of the antibody or antigen-binding portion thereof according to any one of claims 1 to 17, the nucleic acid molecule according to claim 18, the vector according to claim 19, the host cell according to claim 20, the conjugate according to claim 21, the antibody-drug conjugate according to claim 22, the multispecific molecule according to claim 23, or the chimeric antigen receptor according to claim 24, or the pharmaceutical composition or kit according to claim 25 in the preparation of a kit for diagnosing, detecting or monitoring a disease associated with CLDN6 expression.
30. Use of the antibody or antigen-binding portion thereof according to any one of claims 1 to 17, the nucleic acid molecule according to claim 18, the vector according to claim 19, the host cell according to claim 20, the conjugate according to claim 21, the antibody-drug conjugate according to claim 22, the multispecific molecule according to claim 23, or the chimeric antigen receptor according to claim 24, or the pharmaceutical composition or kit according to claim 25 in the preparation of a medicament for treating a disease associated with CLDN6 expression or determining its prognosis.
31. The use according to claim 29 or 30, wherein the disease associated with CLDN6 expression is cancer, and the cancer is preferably selected from the group consisting of ovarian cancer, lung cancer, gastric cancer, breast cancer, liver cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, bladder cancer, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer and uterine cancer.
32. The use according to claim 29 or 30, wherein the disease associated with CLDN6 expression is a fibrotic disease, and the fibrotic disease is preferably selected from fibrosis of the lung, liver, colon, gallbladder, and stomach, and further preferably selected from hepatitis, pulmonary fibrosis, liver fibrosis, cirrhosis, scleroderma, and biliary atresia.
33. The use according to claim 29 or 30, wherein the subject is a mammal, preferably a human.
Citation Information
Patent Citations
Antibodies for treating cancers expressing mitin 6
CN103748112B
Antibodies specific for claudin 6 (CLDN6)
CN111875703A
Sealin-6 antibodies and drug conjugates
CN114174340A
Recombinant DNA methods, vectors and host cells
EP0338841A1
Immunotherapy using interleukin 13 receptor subunit alpha 2
US20020197266A1
Cited By
Antibody-drug conjugate containing Anti-CLDN6 antibody
WO2026098715A1
